

STIC-Biotech/ChemLib

---

**From:** Chan, Christina  
**Sent:** Wednesday, October 01, 2003 4:35 PM  
**To:** Schnizer, Holly; STIC-Biotech/ChemLib  
**Subject:** RE: Request for RUSH sequence search for Appl. no. 09/444,281  
**Importance:** High

Please rush. Thanks Chris

*Chris Chan*

TC 1600 New Hire Training Coordinator and SPE 1644  
308-3973  
CM-1, 9B19

-----Original Message-----

**Fr m:** Schnizer, Holly  
**Sent:** Wednesday, October 01, 2003 4:26 PM  
**To:** Chan, Christina  
**Subject:** Request for RUSH sequence search for Appl. no. 09/444,281

I would like to request the following RUSH sequence search for the above appl. which is an amended due this biweek (Oct. 6).

Please search the commercial and interference databases for the peptide of SEQ ID NO:85 (ILPWKWPWWPWRR)


Thank you.

Holly Schnizer  
AU 1653  
CM1-9E09  
305-3722  
mailbox: CM1-9B01

Searcher: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Location: \_\_\_\_\_  
Date Picked Up: \_\_\_\_\_  
Date Completed: \_\_\_\_\_  
Searcher Prep/Review: \_\_\_\_\_  
Clerical: \_\_\_\_\_  
Online time: \_\_\_\_\_

TYPE OF SEARCH:  
NA Sequences: \_\_\_\_\_  
AA Sequences: \_\_\_\_\_  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

VENDOR/COST (where applic.)  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: \_\_\_\_\_  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_



GenCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:56:42 ; Search time 77 seconds  
(without alignments)  
26.798 Million cell updates/sec

Title: US-09-444-281-85

Sequence: 1 ILPWKMPWMPWRR 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

\_A\_Geneseq\_19Jun03:\*

1: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:\*  
2: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:\*  
3: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:\*  
4: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:\*  
5: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:\*  
6: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:\*  
7: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:\*  
8: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:\*  
9: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:\*  
10: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:\*  
11: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:\*  
12: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:\*  
13: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:\*  
14: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:\*  
15: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:\*  
16: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:\*  
17: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:\*  
18: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:\*  
19: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:\*  
20: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:\*  
21: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:\*  
22: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:\*  
23: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:\*  
24: /SIDS1/gcgdata/geneseq/geneseq-emb1/AA2003.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	99	100.0	13	14	AAAR30970
2	99	100.0	13	16	AAAR78457
3	99	100.0	13	19	AAAY24608
4	99	100.0	13	19	AAAM6441
5	99	100.0	13	20	AAAM87609
6	99	100.0	13	21	AAAY27294
7	99	100.0	13	21	AAAY1740
8	99	100.0	13	21	AAAY1771
9	99	100.0	13	21	AAAY1772

10	99	100.0	13	21	AAAY44666	Crosslink-stabilis
11	99	100.0	13	21	AAAY44324	Antimicrobial pept
12	99	100.0	13	21	AAAY55056	Non-amidated indol
13	99	100.0	13	21	AAAY57123	Naturally occurin
14	99	100.0	13	22	ABPE0382	Indolicidin peptid
15	99	100.0	13	22	ABPE0383	Indolicidin peptid
16	99	100.0	13	22	AAAB1842	Antimicrobial pept
17	99	100.0	13	23	ABAB1940	Peptide fragment o
18	99	100.0	13	23	ABPE59052	Peptide #1. Synth
19	99	100.0	13	23	AAO15551	L-indolicidin carr
20	99	100.0	13	23	ABAB1249	Indolicidin antiba
21	99	100.0	13	23	ABAB1261	Indolicidin antiba
22	99	100.0	13	23	ABAB07699	Bovine cathelicidi
23	99	100.0	13	23	AAU90977	Transplant media a
24	99	100.0	13	24	ABG76068	Human regulatory p
25	99	100.0	13	24	AAE34433	Cow indolicidin pe
26	99	100.0	13	24	ABU59617	Cationic cancer - t
27	99	100.0	13	24	ABRO0800	Bioactive synthe
28	99	100.0	13	24	ABRO0815	Bioactive synthe
29	99	100.0	14	21	AAAY57118	Indolicidin peptid
30	99	100.0	14	21	AAAY57143	Indolicidin peptid
31	99	100.0	15	18	AAW12879	Antimicrobial cati
32	99	100.0	15	24	ABG73946	Cell wall/cell mem
33	99	100.0	16	21	AAAY57144	Indolicidin peptid
34	99	100.0	19	23	AAAB47907	C-terminus of ubiq
35	99	100.0	63	21	AAAY44668	Poly-(Indol (1-13)
36	99	100.0	63	21	AAAY57142	Indolicidin fusion
37	99	100.0	144	23	ABBO7706	Bovine peptide ant
38	96	97.0	13	16	AAAR78459	Indolicidin analog
39	96	97.0	13	22	ABPE0388	Indolicidin peptid
40	96	97.0	15	18	AAW12878	Antimicrobial cati
41	95	96.0	12	21	AAAY44669	Amino terminal tru
42	95	96.0	12	21	AAAY57110	Indolicidin peptid
43	95	96.0	12	22	ABPE0381	Indolicidin peptid
44	94	94.9	12	16	AAAR78458	Indolicidin analog
45	94	94.9	12	21	AAAY57133	Indolicidin peptid

#### ALIGNMENTS

RESULT 1	
AAAR30970	standard; peptide; 13 AA.
ID	AAAR30970;
AC	25-MAR-2003 (updated)
DT	12-MAY-1993 (first entry)
DE	Broad spectrum antimicrobial indolicidin peptide.
DE	Tryptophan rich; microbial; microbistatic; inhibition.
KW	Bos taurus.
OS	MO9222308-A1.
PN	23-DEC-1992.
XX	10-JUN-1992; 92MO-US04920.
PF	14-JUN-1991; 91US-0715271.
XX	(REGC ) UNIV CALIFORNIA.
PA	Cultor JS, Selected ME;
XX	WPI: 1993-017896/02.
DR	Broad spectrum antimicrobial cpd. obtd. from bovine granulocytes -
PT	comprises tryptophan rich peptide, pref. having low immunogenicity
PT	and comprising proline rich peptide or carboxy terminal amide

XX Claim 2; Page 19; 29pp; English.  
 PS The sequence is that of an indolicidin peptide which shows broad  
 CC spectrum antimicrobial activity and when administered to a host does  
 CC not elicit an immune response. It is effective against viruses, gram  
 CC positive bacteria, gram negative bacteria and fungi, including  
 CC Staphylococcus aureus, Escherichia coli, Salmonella typhimurium,  
 CC Listeria monocytogenes, Candida albicans and Cryptococcus neoformans.  
 CC It can be used as a therapeutic agent, food preservative or  
 CC disinfectant, e.g. to purify a water supply. The peptide is pref.  
 CC administered at an effective amt. of 0.5-500 ug/ml final concentration.  
 CC (updated on 25-MAR-2003 to correct PN field.)  
 CC  
 XX SQ Sequence 13 AA;  
 OY  
 Db 1 ILPMKMPMPMPRR 13  
 1 ILPMKMPMPMPRR 13  
 RESULT 2  
 AAR78457 100.0%; Score 99; DB 14; Length 13;  
 ID AAR78457 standard; peptide; 13 AA.  
 XX  
 AC AAR78457;  
 XX  
 DT 25-MAR-1996 (first entry)  
 XX  
 DE Indolicidin analog #4.  
 XX  
 KW Indolicidin; microbicide; therapeutic agent; prophylactic;  
 KW food preservative; disinfectant; medication; Gram positive bacteria;  
 KW Gram negative bacteria; protozoa; yeast; fungi; viruses.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9522338-A1.  
 XX  
 PD 24-AUG-1995.  
 XX  
 PF 10-FEB-1995; 95WO-US01895.  
 XX  
 PR 16-FEB-1994; 94US-0197205.  
 XX  
 PA (REGC ) UNIV CALIFORNIA.  
 XX  
 PI SeIsted ME;  
 PT  
 DR WPI; 1995-302552/39.  
 XX  
 PT Analogues of the tryptophan-rich peptide indolicidin - exhibiting  
 PT broad spectrum antimicrobial activity and selectivity without  
 PT undesirable side effects  
 XX  
 PS Claim 6; Page 27; 37pp; English.  
 XX  
 CC The sequences represented by AAR78454-R78459 are indolicidin analogues.  
 CC These analogues exhibit broad spectrum antimicrobial activity and have  
 CC antimicrobial selectivity when compared to naturally occurring  
 CC indolicidin. The antimicrobial activity of these analogues can be  
 CC altered by incorporation of D-form, chemically altered or synthetic  
 CC amino acids. These sequences can be incorporated into a pharmaceutical  
 CC composition (e.g. as a liposome or non-liposome lipid complex carrier)  
 CC for use in a microbiocidal method. These sequences are active against  
 CC Gram positive and negative bacteria, protozoa, yeast, fungi and viruses.  
 CC They can be used as therapeutic agents, prophylactics, food and preservatives,  
 CC disinfectants or medications. These sequences are easily  
 CC synthesised in an active and effective broad spectrum antimicrobial form

CC with decreased undesirable side effects. Compared to naturally occurring  
 CC indolicidin, these analogues show increased antimicrobial and decreased  
 CC haemolytic activity. Peptide stability, and period of activity within  
 CC the cell can be increased or decreased according to the incorporation of  
 CC D- or L-form amino acids.  
 CC  
 XX SQ Sequence 13 AA;  
 OY  
 Db 1 ILPMKMPMPMPRR 13  
 1 ILPMKMPMPMPRR 13  
 RESULT 3  
 AAY24608 100.0%; Score 99; DB 16; Length 13;  
 ID AAY24608 standard; peptide; 13 AA.  
 XX  
 AC AAY24608;  
 XX  
 DT 18-AUG-1999 (first entry)  
 XX  
 DE Indolicidin analogue #60.  
 XX  
 KW Indolicidin; bacterial infection; photo-oxidised solubiliser;  
 KW antimicrobial; antibiotic; antiarrhythmic; surface disinfectant;  
 KW additive; shampoo; soap; insecticide; herbicide; preservative;  
 KW food; technical material.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9807745-A2.  
 XX  
 PD 26-FEB-1998.  
 XX  
 PF 21-AUG-1997; 97WO-US14779.  
 XX  
 PR 13-JAN-1997; 97US-0034949.  
 XX  
 PR 21-AUG-1996; 96US-0024754.  
 XX  
 PA (MICR-) MICROLOGIX BIOTECH INC.  
 XX  
 PI Erle D, Fraser JR, Krieger TJ, Taylor R, West MH;  
 PT  
 DR WPI; 1998-169090/15.  
 XX  
 PT New indolicidin analogues with antimicrobial activity and related  
 PT nucleic acid - vectors, transformed cells and antibodies, also  
 PT conjugates with polyoxalkylene glycol and fatty acid to reduce  
 PT toxicity, useful therapeutically, as disinfectants etc.  
 XX  
 PS Example 1; Page 32; 129pp; English.  
 XX  
 CC AAY24549 to AAY24615 represent indolicidin analogues of formulae  
 CC (I)-(VIII) containing up to 25 amino acids (aa): RZXXZXB (I), BXZXXZXB  
 CC (II), BBZXXZXB (III), BXZXXZBBN(AA)NMLBAGS (IV), BXZXXZBB(AA)NM  
 CC (V), LBBNXXZBNXRK (VI), LKXZXXZBBN (VII) and BBZXXZBBB (VIII).  
 CC Where Z = P or V; X = hydrophobic residue, preferably W; B = basic aa,  
 CC preferably R or K; AA = any aa; n = 0 or 1; In (II), at least 1 Z = V;  
 CC in (VIII) at least 2 X = F or Y. The analogues are used to treat  
 CC infections caused by bacteria (Gram positive or negative, or anaerobic);  
 CC fungi (yeast or moulds); parasites (protozoa, nematodes, cestodes or  
 CC trematodes) or viruses. Typical of very many pathogens that can be  
 CC controlled are Leishmania, Trypanosoma, Ascaris lumbricoides, Fasciola  
 CC hepatica, Klebsiella pneumoniae, Bordetella pertussis, Staphylococcus  
 CC aureus, Listeria, Clostridium, rotavirus and papilloma virus. Compounds  
 CC derived from the analogues may be used similarly; the compounds may  
 CC also be prepared from antibiotics or antiarrhythmic agents. The analogues  
 CC may be used therapeutically or to coat medical devices; also they are  
 CC useful as surface disinfectants, as additives to shampoo or soaps, as

CC Insecticides or herbicides, or as preservatives for foods and technical  
 CC materials. The analogues are administered by injection, lavage, orally  
 CC or topically, generally at 0.1-50 mg/kg. These analogues have a broader  
 CC spectrum of activity than indolicidin and modification as compounds  
 CC reduces their toxicity.

XX Sequence 13 AA:

Query Match 100.0%; Score 99; DB 19; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKWPMPWRR 13  
 |||||  
 Db 1 ILPMKWPMPWRR 13

RESULT 4

AAW6441 ID AAW6441 standard; peptide; 13 AA.

XX AC AAW6441:

XX DT 12-JAN-1999 (first entry)

XX DE Cationic peptide indolicidin.

XX DE Indolicidin analogue; resistance; cationic peptide; antibiotic;

KW bacterial infection; tolerance; antibacterial; microorganism;

KW bacteria; fungus; parasite; virus.

XX OS Bos taurus.

XX PN WO980401-A2.

XX PD 17-SEP-1998.

XX PF 10-MAR-1998; 98WO-CA00190.

XX PR 25-FEB-1998; 98US-0030619.

XX PR 10-MAR-1997; 97US-0040649.

XX PR 20-AUG-1997; 97US-0915314.

XX PR 26-SEP-1997; 97US-0060099.

XX PA (MICR-) MICROLOGIX BIOTECH INC.

XX PI Fraser JR, McNicol PJ, West MHP;

XX DR WPI; 1998-520800/44.

XX PT New indolicidin peptide analogues - useful for, e.g. enhancing

XX PT activity of antibiotic or overcoming tolerance, acquired resistance

XX PT or inherent resistance of microorganisms

XX PS Disclosure; Page 10; 105pp; English.

XX CC AAW6393 to AAW6469 represent native cationic peptides from the

XX CC present invention. The present invention describes compositions and

XX CC methods for treating infection, especially bacterial infections. The

XX CC compositions and methods use cationic peptides in combination with an

XX CC antibiotic agent which are then administered to a patient to enhance the

XX CC activity of the antibiotic agent, to overcome: (a) tolerance; (b)

XX CC acquired resistance; and (c) inherent resistance. The combinations of

XX CC antibiotics and cationic peptides can provide synergistic activity

XX CC against a microorganism that is tolerant, inherently resistant, or has

XX CC acquired resistance to an antibiotic agent. They can be used for killing

XX CC e.g. bacteria, fungi, parasites and viruses.

XX SQ Sequence 13 AA:

Query Match 100.0%; Score 99; DB 19; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKWPMPWRR 13  
 |||||  
 Db 1 ILPMKWPMPWRR 13

RESULT 5

AAW87609 ID AAW87609 standard; peptide; 13 AA.

XX AC AAW87609;

XX DT 19-MAR-1999 (first entry)

XX DE Antimicrobial peptide indolicidin.

KW Antimicrobial; fusion; acidic peptide; recombinant; microorganism;

KW guamerin; basic peptide; indolicidin.

XX OS Bos sp.

XX PN WO9854336-A1.

XX PD 03-DEC-1998.

XX PF 28-MAY-1998; 98WO-KR00132.

XX PR 09-APR-1998; 98KR-0013372.

XX PR 28-MAY-1997; 97KR-0021312.

XX PA (KOAD ) KOREA ADV INST SCI & TECHNOLOGY.

XX PI (SAMY-) SAMYANG GENEX CORP.

XX PI Hong S, Kang MH, Kim JH, Kim S, Lee H, Lee JH;

XX DR WPI; 1999-059844/05.

XX DR N-PSDB; AAW83788.

XX PT New method for mass production of antimicrobial peptides - by

XX PT constructing fusion genes comprising acidic and antimicrobial

XX PT peptide genes and transforming host with vector containing these

XX PS Example 6; Page 18; 52pp; English.

XX CC The invention relates to mass production of antimicrobial peptides. The

XX CC method comprises constructing a fusion gene containing a first gene

XX CC encoding a negatively charged acidic peptide having at least two cysteine

XX CC residues, and a second gene encoding a positively charged basic

XX CC antimicrobial peptide. A host microorganism is transformed with a vector

XX CC containing the fusion gene and then cultured. The expressed antimicrobial

XX CC peptide is then recovered. The method is used to mass produce

XX CC antimicrobial peptides in recombinant microorganisms. The inhibitory

XX CC effect of the expressed antimicrobial peptide upon the growth of the host

XX CC microorganism is considerably reduced by fusing it to the acidic peptide.

XX CC Therefore, the use of the fusion gene provides an economic, recombinant

XX CC alternative of mass producing antimicrobial peptides, which overcomes the

XX CC disadvantages of low-productivity and poor economy, previously

XX CC encountered by recombinant and chemical methods. The present sequence

XX CC represents an antimicrobial peptide indolicidin. The encoding DNA

XX CC can be used along with the acidic peptide Guamerin gene in the

XX CC construction of the fusion gene.

XX SQ Sequence 13 AA:

Query Match 100.0%; Score 99; DB 20; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKWPMPWRR 13  
 |||||  
 Db 1 ILPMKWPMPWRR 13

RESULT 6  
 ID AAY92794 standard; peptide; 13 AA.  
 AC AAY92794;  
 XX  
 DT 29-AUG-2000 (first entry)  
 XX  
 DE Synthetic antimicrobial peptide; Indolicidin.  
 XX  
 KW Magainin; antimicrobial; transgenic plant; protease degradation; Rev4;  
 KM Indolicidin; protein production; reverse peptide.  
 XX  
 OS Bos taurus.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Modified-site 13  
 FT /note="amidated"  
 XX  
 PN WO200026344-A1.  
 XX  
 PD 11-MAY-2000.  
 XX  
 PE 29-OCT-1999; 99WO-US25561.  
 XX  
 PR 30-OCT-1998; 98US-0106373.  
 PR 02-NOV-1998; 98US-0106537.  
 XX  
 PA (INTE-) INTERLINK BIOTECHNOLOGIES LLC.  
 PA (KENT) UNIV KENTUCKY RES FOUND.  
 XX  
 PI Everett NP, Li Q, Lawrence C, Davies MH;  
 XX  
 DR WPI; 2000-365597/31.  
 XX  
 PT Polypeptides for reducing proteolytic degradation of proteins  
 PT administered to, or produced by a plant comprise indolicin or its  
 XX functional equivalents  
 XX  
 PS Example 2; Page 15; 50pp; English.  
 XX  
 CC Indolicidin is a potent antimicrobial tridecapeptide, originally  
 CC purified from cytoplasmic granules of bovine neutrophils. A reverse  
 CC peptide, Rev4 (AAY92796) of indolicidin was found to have increased  
 CC stability against plant protease degradation. Expression of antimicrobial  
 CC peptides in transgenic plants suffers a major limitation in that the  
 CC foreign peptides are susceptible to rapid degradation by proteases. The  
 CC invention concerns reducing the extent of protease degradation of a  
 CC protein applied to, or produced by a plant by administering indolicidin,  
 CC Rev4 or a functional equivalent to the plant. Transgenic plants  
 CC expressing indolicidin and Rev4 are useful for production of the  
 CC antimicrobial peptides. Compositions containing indolicidin and Rev4 are  
 CC also useful for production of agronomically important proteins in  
 CC plants.  
 CC  
 XX  
 SQ Sequence 13 AA:  
 Query Match 100.0%; Score 99; DB 21; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ILPKWPMWPMRR 13  
 ||||||||||||  
 DB 1 ILPKWPMWPMRR 13  
 RESULT 7  
 ID AAY91740 standard; Peptide; 13 AA.  
 AC AAY91740;  
 XX

DT 06-JUN-2000 (first entry)  
 XX  
 DE Cationic peptide Indolicidin amino acid sequence.  
 XX  
 KW Cationic peptide; tumour; pharmaceutical composition; cancer; treatment;  
 KW leukaemia; polyoxalylkene-modified; APO; lymphoma; multiple myeloma;  
 KW breast; lung; ovary; cervix; uterus; skin; prostate; liver; colon;  
 KW multidrug resistance.  
 XX  
 OS Unidentified.  
 XX  
 PN WO9965506-A2.  
 XX  
 PD 23-DEC-1999.  
 XX  
 PE 14-JUN-1999; 99WO-CA00552.  
 XX  
 PR 12-JUN-1998; 98US-0096541.  
 XX  
 PA (MICR-) MICROLOGIX BIOTECH INC.  
 XX  
 PI Friedland HD, Krieger TJ, Taylor R, Erile D, Fraser JR, West MHP;  
 XX  
 DR WPI; 2000-223549/19.  
 XX  
 PE Novel pharmaceutical composition containing optionally activated  
 PT polyoxalylkene-modified cationic peptides, useful for treating tumours  
 PT  
 XX  
 PS Disclosure; Page 11; 94pp; English.  
 XX  
 CC This sequence represents a cationic peptide amino acid sequence, which  
 CC can be used in the pharmaceutical composition of the invention. The  
 CC invention relates to a pharmaceutical composition containing at least one  
 CC activated polyoxalylkene (APO)-modified cationic peptide. The  
 CC modification of peptides with APO increases their activity against tumour  
 CC cells, including those with a multidrug resistant phenotype. The  
 CC pharmaceutical composition can be used to treat tumours, specifically  
 CC lymphoma, leukaemia, multiple myeloma, or tumours of breast, lung, ovary,  
 CC cervix, uterus, skin, prostate, liver and colon.  
 CC  
 XX  
 SQ Sequence 13 AA:  
 Query Match 100.0%; Score 99; DB 21; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ILPKWPMWPMRR 13  
 ||||||||||||  
 DB 1 ILPKWPMWPMRR 13  
 RESULT 8  
 ID AAY91771 standard; Peptide; 13 AA.  
 AC AAY91771;  
 XX  
 DT 06-JUN-2000 (first entry)  
 XX  
 DE Amino acid sequence of cationic peptide MBI 10.  
 XX  
 KW Cationic peptide; tumour; pharmaceutical composition; cancer; treatment;  
 KW leukaemia; polyoxalylkene-modified; APO; lymphoma; multiple myeloma;  
 KW breast; lung; ovary; cervix; uterus; skin; prostate; liver; colon;  
 KW multidrug resistance.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9965506-A2.  
 XX  
 PD 23-DEC-1999.  
 XX

PF 14-JUN-1999; 99WO-CA00552.  
XX  
XX 12-JUN-1998; 98US-0096541.  
XX  
XX (MICR-) MICROLOGIX BIOTECH INC.  
XX  
XX Friedland HD, Krieger TJ, Taylor R, Erfle D, Fraser JR, West MHP;  
XX WPI: 2000-223549/19.  
XX  
XX  
XX Novel pharmaceutical composition containing optionally activated  
PT polyoxalkylene-modified cationic peptides, useful for treating tumours  
PT  
XX  
XX Disclosure: Page 14; 94pp; English.  
XX  
XX This sequence represents a cationic peptide amino acid sequence, which  
CC can be used in the pharmaceutical composition of the invention. The  
CC invention relates to a pharmaceutical composition containing at least one  
CC activated polyoxalkylene (APO)-modified cationic peptide. The  
CC modification of peptides with APO increases their activity against tumour  
CC cells, including those with a multidrug resistant phenotype. The  
CC pharmaceutical composition can be used to treat tumours, specifically  
CC lymphoma, leukaemia, multiple myeloma, or tumours of breast, lung, ovary,  
CC cervix, uterus, skin, prostate, liver and colon.  
XX  
XX  
SQ Sequence 13 AA:  
Query Match 100.0%; Score 99; DB 21; Length 13;  
Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1 ILPWKMPWMPWR 13  
Db 1 ILPWKMPWMPWR 13  
RESULT 9  
AA91772  
ID AAY91772 standard; Peptide; 13 AA.  
XX  
XX AAY91772;  
AC  
XX  
XX 06-JUN-2000 (first entry)  
DT  
XX  
XX Amino acid sequence of cationic peptide MBI 10CN.  
DE  
XX  
XX Cationic peptide; tumour; pharmaceutical composition; cancer; treatment;  
KW leukaemia; polyoxalkylene-modified; APO; lymphoma; multiple myeloma;  
KW breast; lung; ovary; cervix; uterus; skin; prostate; liver; colon;  
KW multidrug resistance.  
XX  
XX Synthetic.  
OS  
XX  
XX WO9965506-A2.  
XX  
XX 23-DEC-1999.  
PD  
XX  
XX 14-JUN-1999; 99WO-CA00552.  
PF  
XX  
XX 12-JUN-1998; 98US-0096541.  
PR  
XX  
XX (MICR-) MICROLOGIX BIOTECH INC.  
PA  
XX  
XX Friedland HD, Krieger TJ, Taylor R, Erfle D, Fraser JR, West MHP;  
XX WPI: 2000-223549/19.  
XX  
XX  
XX Novel pharmaceutical composition containing optionally activated  
PT polyoxalkylene-modified cationic peptides, useful for treating tumours  
PT  
XX  
XX Disclosure: Page 14; 94pp; English.

XX  
XX This sequence represents a cationic peptide amino acid sequence, which  
CC can be used in the pharmaceutical composition of the invention. The  
CC invention relates to a pharmaceutical composition containing at least one  
CC activated polyoxalkylene (APO)-modified cationic peptide. The  
CC modification of peptides with APO increases their activity against tumour  
CC cells, including those with a multidrug resistant phenotype. The  
CC pharmaceutical composition can be used to treat tumours, specifically  
CC lymphoma, leukaemia, multiple myeloma, or tumours of breast, lung, ovary,  
CC cervix, uterus, skin, prostate, liver and colon.  
XX  
XX  
SQ Sequence 13 AA:  
Query Match 100.0%; Score 99; DB 21; Length 13;  
Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1 ILPWKMPWMPWR 13  
Db 1 ILPWKMPWMPWR 13  
RESULT 10  
AA44666  
ID AAY44666 standard; peptide; 13 AA.  
XX  
XX AAY44666;  
AC  
XX  
XX 18-APR-2000 (first entry)  
DT  
XX  
XX Crosslinked indolicidin analog Indol 1-13(W6/9).  
DE  
XX  
XX Crosslinked indolicidin analog; X-indolicidin; Indol 1-13(W6/9);  
KW stability; bovine neutrophil; antimicrobial; antibacterial; fungicide;  
KW protozoacide; virucide; anti-HIV; human immunodeficiency virus-1;  
KW HIV-1; gram positive bacteria; gram negative; Staphylococcus aureus;  
KW Escherichia coli; Salmonella typhimurium; yeast; fungi; protozoa;  
KW Candida albicans; Cryptococcus neoformans; Giardia; Acanthamoeba.  
XX  
XX  
OS Synthetic.  
OS  
XX Bos sp.  
XX  
XX Key Location/Qualifiers  
FH Modified-site 6..9  
FT /note="Residues at positions 6 and 9 form a  
FT di-tryptophan crosslink"  
FT 13  
FT Modified-site /note="C-terminal amide"  
XX  
XX WO9965510-A1.  
XX  
XX 23-DEC-1999.  
PD  
XX  
XX 20-MAY-1999; 99WO-US11165.  
PF  
XX  
XX 18-JUN-1998; 98US-0099631.  
PR  
XX  
XX (REBC ) UNIV CALIFORNIA.  
PA  
XX  
XX Selsted ME, Osapay K;  
XX WPI: 2000-147133/13.  
XX  
XX Crosslinked indolicidin analogs with antimicrobial activity against  
PT bacteria, yeast, fungi, protozoa and viruses  
PT  
XX  
XX Claim 3; Page 39; 53pp; English.  
XX  
XX The patent discloses crosslinked analogs of indolicidin (Indol 1-13)  
CC which is a naturally occurring peptide isolated from bovine neutrophils  
CC and has antimicrobial activity. The crosslinked indolicidin  
CC (X-indolicidin) analogs are stable and have antimicrobial activity  
CC against gram positive and negative bacteria (e.g. Staphylococcus aureus,

CC Escherichia coli and Salmonella typhimurium), yeasts and fungi (e.g. Candida albicans, Cryptococcus neoformans), protozoa (e.g. Giardia species and Acanthamoeba species), and viruses (e.g. HIV-1). They can be used for reducing or inhibiting the growth or survival of microorganisms in an environment e.g. a food or food product, a solution, an inanimate object comprising a surface, or a mammal. CC The present sequence is a specifically claimed X-indolicidin analog, Indol 1-13(W6/9) which contains a di-tryptophan crosslink. CC XX

Sequence 13 AA;  
Query Match 100.0%; Score 99; DB 21; Length 13;  
Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPMPRR 13  
Db 1 ILPMKMPMPMPRR 13

## RESULT 11

AAV44324  
ID AAV44324 standard; peptide; 13 AA.

XX AAV44324;

DT 29-FEB-2000 (first entry)

XX Antimicrobial peptide, Indolicidin.

XX purf gene: glutamine pyrophosphoribosyl pyrophosphatase;

KW purf derivative; fusion partner; antimicrobial peptide; indolicidin;

KM mass production; cleavage site; hydroxylamine; CNBr; DNA construct; cow;

KX neutralise; toxicity; pharmaceutical industry; food industry.

OS Bos taurus.

XX WO9964611-A1.

XX 16-DEC-1999.

XX 08-JUN-1999; 99WO-KR00282.

XX 09-JUN-1998; 98KR-0022117.

PR 14-MAY-1999; 99KR-0017920.

XX (SAMY-) SAMYANG GENEX CORP.

PI Kim JH, Kang MH, Lee J, Park SH, Lee JW, Hong SS, Lee H;

XX WPL 2000-097542/08.

DR N-PSDB; AA244324.

PT New DNA constructs useful for mass production of antimicrobial peptides

PS Claim 1; Fig 1; 67pp; English.

XX The present amino acid sequence is an antimicrobial peptide, Indolicidin

CC derived from cow, Bos taurus. It is used along with a

CC A DNA construct that comprises, this antimicrobial peptide encoding

CC sequence and the entire, partial or derivative of purf gene, is used for

CC mass production of the antimicrobial peptide in microorganisms without

CC killing the host cells. Use of the purf gene derivative sequence,

CC neutralises the toxicity of the antimicrobial peptides against the host

CC microorganism. The antimicrobial peptides are useful commercially in the

CC pharmaceutical and food industries.

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPMPRR 13  
Db 1 ILPMKMPMPMPRR 13

## RESULT 12

AAV55056  
ID AAV55056 standard; peptide; 13 AA.

XX AAV55056;

DT 23-FEB-2000 (first entry)

XX Non-amidated indolicidin peptide.

XX Indolicidin; bactericidal; sulphate-reducing bacteria; growth inhibitor;

KW corrosion; degradation; metal; concrete; cement; dental implant; biofilm.

XX Bacillus sp.

XX WO9965553-A1.

XX 11-NOV-1999.

XX 03-MAY-1999; 99WO-US09675.

XX 06-MAY-1998; 98US-0074037.

PR 31-MAR-1999; 99US-0282277.

XX (REBC ) UNIV CALIFORNIA.

PI Wood TK, Jayaraman A, Earltman JC;

XX WPL 2000-052882/04.

XX Inhibiting growth of sulphate-reducing bacteria using other bacteria,

XX particularly for protection of metals and concrete

XX Example 4; Page 41; 84pp; English.

XX This sequence represents the non-amidated indolicidin peptide.

CC The invention relates to a method for inhibiting growth of

CC sulphate-reducing bacteria (A) on a material (B) sensitive to corrosion

CC or degradation, by applying to (B) a bacterium (C) that secretes a

CC compound (I) able to inhibit growth of (A). The method is used to protect

CC metal, concrete or cement against corrosion and degradation, but (B) can

CC also be used to protect dental implants. (B) is present in an open or

CC closed system (e.g. water cooling tower, liquid storage container, fuel

CC tank, sewer or drainage system etc.) or part of a bridge or other

CC structure. The method is more effective and less expensive than known

CC methods for inhibiting (A), and reduces the amount of toxic chemicals

CC released. Conventional biofilms of aerobic organisms tend to encourage

CC growth of (A), and addition of (C) to the biofilm prevents this. A

CC single application of (C) lasts for a long time, and (I) are produced

CC exactly where they are required and inhibit (A) without significant

CC impact on other organisms (this effect includes reducing resistance of

CC (A) to conventional biocides, which may then be used in reduced

CC amounts). If local damage to the biofilm occurs, the underlying

Sequence 13 AA;

Query Match 100.0%; Score 99; DB 21; Length 13;

Best Local Similarity 100.0%; Pred. No. 9.8e-07; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0;

QY 1 ILPMKMPMPMPRR 13

Db 1 ILPMKMPMPMPRR 13



RESULT 13  
AAV57123  
ID AAV57123 standard; peptide: 13 AA.  
XX  
AC AAV57123;  
XX  
DT 28-FEB-2000 (first entry)  
XX  
DE Naturally occurring bovine indolicidin peptide Indol 1-13.  
XX  
KW Indolicidin analogue; antimicrobial activity; helminth; bacteria; virus;  
KW treatment; inhibit growth; micro-organism; contact lens solution;  
KW transgenic plant; surgical instrument; yeast; fungi; protozoa.  
XX  
OS Bos sp.  
XX  
FH Key Location/Qualifiers  
FH Modified-site 13 /note="C-terminal amide"  
XX  
PN WO958141-A1.  
XX  
PD 18-NOV-1999.  
XX  
PF 05-MAY-1999; 99WO-US09942.  
XX  
PR 12-MAY-1998; 98US-0076227.  
XX  
PA (REGC ) UNIV CALIFORNIA.  
XX  
PI Selsted ME;  
XX  
DR WPI; 2000-053028/04.  
XX  
PT New indolicidin analogues, active against bacteria, yeast, fungi,  
PT protozoa and virus, used for, e.g. treating infections -  
XX  
PS Example 1; Page 28; 62pp: English.  
XX  
CC This sequence is a naturally occurring indolicidin peptide.  
CC Peptides AAV57109-Y57138 and AAV57143-Y57144s are new indolicidin  
CC analogues, which have a homoserine residue and/or a truncated amino  
CC terminal region. The analogues have the following amino acid sequence:  
CC Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Pro-Xaa6-Xaa6-Xaa7-Xaa7-Xaa8  
CC where:  
CC Xaa1 = Ile, Leu, Val, Ala, Gly or absent;  
CC Xaa2 = Ile, Leu, Val, Ala, Gly or absent;  
CC Xaa3 = Pro or absent;  
CC Xaa4 = Trp, Phe or absent;  
CC Xaa5 = Arg, Lys or absent;  
CC Xaa6 = Trp or Phe;  
CC Xaa7 = Arg, Lys or absent;  
CC Xaa8 = homoserine (Hse), Met, Met-Xaa9-Met or absent, and  
CC Xaa9 = at least one amino acid;  
CC provided that if Xaa1 is present, Xaa8 = Hse, Met or Met-Xaa9-Met;  
CC and further provided that: if Xaa2 is absent, Xaa1 is absent; if Xaa3 is  
CC absent, Xaa1 and Xaa2 are absent; if Xaa4 is absent, Xaa1, Xaa2 and Xaa3  
CC are absent; and if Xaa5 is absent, Xaa1, Xaa2, Xaa3 and Xaa4 are absent.  
CC The indolicidin analogues can be used to create a fusion polypeptide  
CC consisting of the analogue linked to a peptide. The indolicidin  
CC analogues have antimicrobial activity against gram positive bacteria,  
CC gram negative bacteria, yeast, fungus, protozoa and viruses (e.g. HIV-1).  
CC They are also active against helminths. The analogues can be used for  
CC reducing or inhibiting growth or survival of a microorganism. They can be  
CC used for treating infections. They can also be included in a liquid such  
CC as water or an aqueous solution, e.g. contact lens solution. The  
CC analogues have potential uses in food products, and in objects such as  
CC the surface of an instrument used to prepare food or to perform surgery.  
CC Transgenic plants or animals useful in the food industry can be produced  
CC by introducing a nucleic acid molecule encoding an indolicidin analogue  
CC into the germ-line cells of such organisms.  
XX  
SQ Sequence 13 AA;

Query Match 100.0%; Score 99; DB 21; Length 13;  
Best Local Similarity 100.0%; Pred. No. 9.8e-07;  
Matches 13: Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1 ILPMKMPWMPMR 13  
| | | | | | | | | | | | | | |  
Db 1 ILPMKMPWMPMR 13  
RESULT 14  
ABP60382  
ID ABP60382 standard; peptide: 13 AA.  
XX  
AC ABP60382;  
XX  
DT 28-MAR-2003 (first entry)  
XX  
DE Indolicidin peptide SEQ ID NO 1.  
XX  
KW Indolicidin; ophthalmic; disinfection; contact lens; antimicrobial;  
KW Pseudomonas aeruginosa; Staphylococcus aureus; Serratia marcescens;  
KW Candida albicans; Fusarium solani.  
XX  
OS Unidentified.  
XX  
FH Key Location/Qualifiers  
FH Modified-site 13 /note="C-terminal CONH2"  
XX  
PN WO20071175-A1.  
XX  
PD 30-NOV-2000.  
XX  
PF 23-MAY-2000; 2000WO-US14608.  
XX  
PR 25-MAY-1999; 99US-0318195.  
XX  
PA (LARG-) LARGE SCALE BIOLOGY CORP.  
XX  
PA (STRI-) SRI INTL.  
XX  
PA (REGC ) UNIV CALIFORNIA.  
XX  
PA (WESL-) WESLEY-JESSEN CORP.  
XX  
PA (TUSE/) TUSE D.  
XX  
PA (MORT/) MORTELMANS K.  
XX  
PA (HOKA/) HOKAMA L A.  
XX  
PA (SELS/) SELSTED M E.  
XX  
PA (CHAP/) CHAPOY L L.  
XX  
PA (QUIN/) QUINN M H.  
XX  
PI Tuse D, Mortelmans K, Hokama LA, Selsted ME, Chapoy LL, Quinn MH;  
PI WPI; 2001-080322/09.  
XX  
DR Ophthalmic composition for storing, cleaning, or disinfecting contact  
XX lens, comprises indolicidin, and buffer having specified halide ion  
XX concentration or Good's buffer -  
XX  
PT Claim 15; Page 68; 91pp: English.  
XX  
PS The invention relates to an ophthalmic composition (I) for storing,  
XX cleaning, or disinfecting a contact lens, comprising an indolicidin  
XX antimicrobial peptide and a buffer having a halide ion concentration less  
XX than 0.85 weight%, based on the total weight of (I) or Good's buffer. (I)  
XX is a multipurpose solution for care of a contact lens and is suitable for  
XX contact lens disinfection, storage, cleaning, conditioning, rehydrating,  
XX moistening and lubricating. (I) is useful for disinfecting the contact  
XX lens or contact lens storage vessel such as contact lens vial, contact  
XX lens case or a contact lens shipping package by contacting the lens or  
XX vessel with a disinfecting solution comprising (I). (I) is useful for  
XX packaging a contact lens involving sealing the lens in a container with  
XX (I), where the contact lens is not autoclaved. (I) reduces the number of  
XX Pseudomonas aeruginosa, Staphylococcus aureus and Serratia marcescens  
XX organisms by 3.0 logs or more within 4 hours and the number of Candida

CC albicans and Fusarium solani by 1.0 log or more within 18 hours. (1) is  
 CC self-preserving and requires no additional preservatives or  
 CC disinfectants. Since indolicidin are safe for topical application to the  
 CC eye, (1) enables immediate application of the contact lens to the eye  
 CC without the need for neutralisation, deactivation or washing any of the  
 CC components of (1). The present sequence is that of an indolicidin peptide  
 CC of the invention.

XX Sequence 13 AA;

Query Match 100.0%; Score 99; DB 22; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKRWPMWPMRR 13  
 |||  
 Db 1 ILPMKRWPMWPMRR 13

RESULT 15

ABP60383 standard; peptide; 13 AA.

XX ABP60383;

DT 28-MAR-2003 (first entry)

DE Indolicidin peptide SEQ ID NO 2.

XX Indolicidin; ophthalmic; disinfection; contact lens; antimicrobial;

KW Pseudomonas aeruginosa; Staphylococcus aureus; Serratia marcescens;

KM Candida albicans; Fusarium solani.

XX Unidentified.

OS Key Location/Qualifiers  
 FH Modified-site 13 /note="C-terminal OH"

PN WO200071175-A1.

XX 30-NOV-2000.

PF 23-MAY-2000; 2000WO-US14608.

XX 25-MAY-1999; 99US-0318195.

XX (LARG-) LARGE SCALE BIOLOGY CORP.

PA (STRI) SRI INT.

PA (REGC) UNIV CALIFORNIA.

PA (WEST-) WESLEY-JESSEN CORP.

PA (TUSE-) TUSE D.

PA (MORT/) MORTELMANS K.

PA (HOKA/) HOKAMA L A.

PA (SELS/) SELSTED M E.

PA (CHAP/) CHAPOY L L.

PA (QUINN/) QUINN M H.

XX Tuse D, Morielmans K, Hokama LA, Selsted ME, Chapoy LL, Quinn MH;

XX WPI; 2001-080322/09.

XX Ophthalmic composition for storing, cleaning, or disinfecting contact

CC lens, comprises indolicidin, and buffer having specified halide ion

CC concentration or Good's buffer

CC Disclosure; Page 16; 91pp; English.

CC contact lens disinfection, storage, cleaning, conditioning, rehydrating,  
 CC mistensing and lubricating. (1) is useful for disinfecting the contact  
 CC lens or contact lens storage vessel such as contact lens vial, contact  
 CC lens case or a contact lens shipping package by contacting the lens or  
 CC vessel with a disinfecting solution comprising (1). (1) is useful for  
 CC packaging a contact lens involving sealing the lens in a container with  
 CC (1), where the contact lens is not autoclaved. (1) reduces the number of  
 CC Pseudomonas aeruginosa, Staphylococcus aureus and Serratia marcescens  
 CC organisms by 3.0 logs or more within 4 hours and the number of Candida  
 CC albicans and Fusarium solani by 1.0 log or more within 18 hours. (1) is  
 CC self-preserving and requires no additional preservatives or  
 CC disinfectants. Since indolicidin are safe for topical application to the  
 CC eye, (1) enables immediate application of the contact lens to the eye  
 CC without the need for neutralisation, deactivation or washing any of the  
 CC components of (1). The present sequence is that of an indolicidin peptide  
 CC of the invention.

SQ Sequence 13 AA;

Query Match 100.0%; Score 99; DB 22; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 9.8e-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKRWPMWPMRR 13  
 |||  
 Db 1 ILPMKRWPMWPMRR 13

Search completed: October 2, 2003, 10:01:28

Job time : 78 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:59:37 ; Search time 41 Seconds

(without alignments)  
30.493 Million cell updates/sec

Title: US-09-444-281-85

Perfect score: 99

Sequence: 1 ILPMKMPMPWRR 13

Scoring table:

BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

1: p1r1:\*  
2: p1r2:\*  
3: p1r3:\*  
4: p1r4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	99	100.0	144	1 UC1222	indolicidin precursor
2	54	54.5	1173	1 VGIHHC	E2 glycoprotein pr
3	53.5	54.0	299	2 T12505	hypothetical prote
4	53	53.5	327	2 E72851	Acotf-13 protein -
5	53.5	53.5	331	2 T41758	ACMPV orf13 - Bom
6	51	51.5	55	2 E90626	ATP synthase F0 ch
7	51	51.5	689	2 AC1927	hypothetical prote
8	51	51.5	1038	2 I38935	bone morphogenetic
9	50.5	51.0	970	2 T28234	ORF MSV076 probabl
10	50	50.5	83	2 B72392	hypothetical prote
11	50	50.5	337	2 G95922	probable glycosylt
12	50.5	49.8	1	1 J70751	ferredoxin-NADP re
13	49.5	50.0	296	2 T03562	conserved hypothet
14	49	49.5	60	2 A56547	sex-peptide precu
15	49	49.5	425	2 E84631	probable serine ca
16	49	49.5	111	2 E89605	protein F18G5.2 [1
17	48.5	49.0	167	2 T29295	hypothetical prote
18	48	48.5	55	2 T11105	H+-transporting tw
19	48	48.5	265	2 AH0755	conserved hypothet
20	48	48.5	400	2 AF2107	hypothetical prote
21	47	47.5	55	1 PAXL8	H+-transporting tw
22	47	47.5	55	2 S68132	H+-transporting tw
23	47	47.5	55	2 S08424	H+-transporting tw
24	47	47.5	55	2 E90618	ATP synthase F0 ch
25	47	47.5	55	2 T11538	H+-transporting tw
26	47	47.5	55	2 T11184	H+-transporting tw
27	47	47.5	55	2 T11291	H+-transporting tw
28	47	47.5	55	2 T09861	H+-transporting tw
29	47	47.5	55	2 T09951	H+-transporting tw

30	47	47.5	55	2 T11768	H+-transporting tw
31	47	47.5	55	2 T11304	H+-transporting tw
32	47	47.5	248	2 S23449	NADH oxidase (H2O2
33	47	47.5	253	2 G70715	hypothetical prote
34	47	47.5	297	2 D87260	integral membrane
35	47	47.5	456	2 T18963	hypothetical prote
36	47	47.5	496	2 A54770	N-acetylglucosamin
37	47	47.5	534	1 S75101	hypothetical prote
38	47	47.5	728	2 T51071	related to tria pr
39	47	47.5	1112	2 S70522	cyclic nucleotide
40	46.5	47.0	1299	2 AB2244	hypothetical prote
41	46	46.5	54	1 S04619	H+-transporting tw
42	46	46.5	55	2 T11171	H+-transporting tw
43	46	46.5	55	2 T12413	H+-transporting tw
44	46	46.5	55	2 E58892	H+-transporting tw
45	46	46.5	55	2 E90612	ATP synthase F0 ch

#### ALIGNMENTS

##### RESULT 1

JC1222

Indolicidin precursor - bovine

N:Alternate names: antimicrobial peptide

C:Species: Bos primigenius taurus (cattle)

C:Date: 10-Sep-1999 #sequence, revision 10-Sep-1999 #text\_change 10-Sep-1999

C:Accession: JC1222; A42387; S25664

R:del Sal, G.; Storici, P.; Schneider, C.; Romeo, D.; Zanetti, M.

A:Title: CDNA cloning of the neutrophil bactericidal peptide indolicidin.

A:Reference number: JC1222; MUID:92392368; PMID:1520337

A:Accession: JC1222

A:Molecule type: mRNA

A:Residues: 1-144 <SAL>

A:Cross-references: EMBL:X67340; NID:g462; PIDN:CAA47755.1; PID:g463

A:Experimental source: bone marrow

R:Selected, M.E.; Novotny, M.J.; Morris, W.L.; Tang, Y.Q.; Smith, W.; Cullor, J.S.

J. Biol. Chem. 267, 4292-4295, 1992

A:Title: Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils.

A:Reference number: A42387; MUID:92165771; PMID:1537821

A:Accession: A42387

A:Molecule type: protein

A:Residues: 131-143 <SRL>

A:Experimental source: neutrophils

A:Note: sequence extracted from NCBI backbone (NCBI:83840)

C:Superfamily: cathelin; cystatin homology

C:Keywords: amidated carboxyl end

F:1-29/Domain: signal sequence #status predicted <Sig>

F:30-130/Domain: propeptide #status predicted <Pro>

F:131-143/Product: indolicidin #status experimental <Mat>

F:143/Modified site: amidated carboxyl end (Arg) (amide in mature form from following

Query Match 100.0%; Score 99; DB 1; Length 144;

Best local Similarity 100.0%; Pred. No. 7.4e-06;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
Db 131 ILPMKMPMPWRR 143

##### RESULT 2

VG1HHC E2 glycoprotein precursor - human coronavirus (strain 229E)

N:Alternate names: peplomer glycoprotein; S glycoprotein; spike glycoprotein

C:Species: human coronavirus

A:Note: host Homo sapiens (man)

C:Date: 31-Dec-1991 #sequence, revision 31-Dec-1991 #text\_change 16-Jun-2000

C:Accession: A34766; S05460

R:Raabe, T.; Schelle-Pinz, B.; Siddell, S.G.

J. Gen. Virol. 71, 1065-1073, 1990

A:Title: Nucleotide sequence of the gene encoding the spike glycoprotein of human corona  
A:Reference number: A34766; MUID:90264837; PMID:2345367  
A:Accession: A34766  
A:Molecule type: mRNA  
A:Residues: 1-1173 <RAA>  
A:Cross-references: EMBL:X16816; NID:958926; PIDN:CAA34723.1; PID:958927  
A:Experimental source: strain 229E  
R:Rabe, T.; Siddell, S.  
Nucleic Acids Res. 17, 6387, 1989  
A:Title: Nucleotide sequence of the human coronavirus HCV 229E mRNA 4 and mRNA 5 unique  
A:Reference number: A34038; MUID:89366667; PMID:2701946  
A:Accession: S05460  
A:Status: translation not shown  
A:Molecule type: mRNA  
A:Residues: 1159-1173 <RA2>  
A:Cross-references: EMBL:X16564; NID:958921; PIDN:CAA33680.1; PID:91334827  
C:Superfamily: coronavirus E2 glycoprotein  
C:Keywords: glycoprotein; transmembrane protein  
F:1-15/Domain: signal sequence #status predicted <SIG>  
F:16-1173/Product: E2 glycoprotein #status predicted <MAT>  
F:1116-1138/Domain: transmembrane #status predicted <TMN>  
F:23,62,98,147,171,176,220,243,326,333,440,464,518,538,542,568,581,587,663,671,930,1015,  
Query Match 54.5%; Score 54; DB 1; Length 1173;  
Best Local Similarity 85.7%; Pred. No. 21;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 5 KPWMPW 11  
||| |  
Db 1113 KPWMPW 1119  
||| |  
RESULT 3  
T12505  
hypothetical protein DKFZp434C192.1 - human (fragment)  
C:Species: Homo sapiens (man)  
C:Date: 23-Jul-1999 #sequence\_revision 23-Jul-1999 #text\_change 23-Jul-1999  
C:Accession: T12505  
R:Ansorge, W.; Witkner, U.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.  
submitted to the Protein Sequence Database, June 1999  
A:Reference number: Z17527  
A:Accession: T12505  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-299 <ANS>  
A:Cross-references: EMBL:AL096753  
A:Experimental source: adult testis; clone DKFZp434C192  
C:Genetics:  
A:Note: DKFZp434C192.1  
Query Match 54.0%; Score 53.5; DB 2; Length 299;  
Best Local Similarity 57.1%; Pred. No. 6.4;  
Matches 8; Conservative 0; Mismatches 3; Indels 3; Gaps 1;  
OY 3 PW--KMPWPMRR 13  
|| |  
Db 30 PWSASPMWPMR 43  
|| |  
RESULT 4  
E72851  
AcOrf-13 protein - Autographa californica nuclear polyhedrosis virus  
C:Species: Autographa californica nuclear polyhedrosis virus, AcMNPV  
A:Note: dsDNA virus  
C:Date: 12-Nov-1999 #sequence\_revision 12-Nov-1999 #text\_change 12-Nov-1999  
C:Accession: E72851  
R:Rayes, M.D.; Howard, S.C.; Kuzio, J.; Lopez-Ferber, M.; Possee, R.D.  
Virology 202, 586-605, 1994  
A:Title: The complete DNA sequence of Autographa californica nuclear polyhedrosis virus.  
A:Reference number: A72850; MUID:94303173; PMID:8030224  
A:Accession: E72851  
A:Status: preliminary  
A:Molecule type: DNA

A:Residues: 1-327 <AYR>  
A:Cross-references: GB:L22858; NID:9510708; PIDN:AAA6643.1; PID:9559082  
C:Genetics:  
A:Gene: AcOrf-13  
Query Match 53.5%; Score 53; DB 2; Length 327;  
Best Local Similarity 54.5%; Pred. No. 8;  
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
OY 1 ILPMKMPW 11  
: | | | |  
Db 1 MLSTLMWMMW 11  
: | | | |  
RESULT 5  
T41758  
AcMNPV orf13 - Bombyx mori nuclear polyhedrosis virus (isolate T3)  
C:Species: Bombyx mori nuclear polyhedrosis virus, BmsNPV  
A:Variety: isolate T3  
C:Date: 03-Dec-1999 #sequence\_revision 03-Dec-1999 #text\_change 21-Jul-2000  
C:Accession: T41758  
R:Gomi, S.; Majima, K.; Maeda, S.  
J. Gen. Virol. 80, 1323-1337, 1999  
A:Title: Sequence analysis of the genome of Bombyx mori nucleopolyhedrovirus.  
A:Reference number: Z22020; MUID:99281911; PMID:10355780  
A:Accession: T41758  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: DNA  
A:Residues: 1-331 <RAM>  
A:Cross-references: EMBL:L33180; NID:93745835; PIDN:AAC63687.1; PID:93745840  
A:Experimental source: isolate T3  
C:Genetics:  
A:Note: Orf\_5  
Query Match 53.5%; Score 53; DB 2; Length 331;  
Best Local Similarity 54.5%; Pred. No. 8.1;  
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
OY 1 ILPMKMPW 11  
: | | | |  
Db 1 MLSTLMWMMW 11  
: | | | |  
RESULT 6  
E90626  
ATP synthase F0 chain 8 [imported] - Eudromia elegans mitochondrion  
C:Species: mitochondrion Eudromia elegans  
C:Date: 15-Jun-2001 #sequence\_revision 15-Jun-2001 #text\_change 17-May-2002  
C:Accession: E90626  
R:Hadrath, O.; Baker, A.J.  
Proc. R. Soc. Lond. B Biol. Sci. 268, 939-945, 2001  
A:Title: Complete mitochondrial DNA genome sequences of extinct birds: rattle phylog  
A:Reference number: A99613; MUID:21263106; PMID:11370967  
A:Accession: E90626  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-55 <KUR>  
A:Cross-references: GB:NC\_002772; NID:914141818; PIDN:NP\_115277.1; GSPDB:GN00163  
C:Genetics:  
A:Gene: ATP8  
A:Genome: mitochondrion  
A:Genetic code: SGC1  
C:Superfamily: H+-transporting ATP synthase protein 8  
C:Keywords: mitochondrion  
Query Match 51.5%; Score 51; DB 2; Length 55;  
Best Local Similarity 85.7%; Pred. No. 2.5;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 2 LPMKMPW 8  
|| |  
Db 48 LPMKMPW 54  
|| |

```

RESULT 7
AC1927
hypothetical protein all0966 [imported] - Nostoc sp. (strain PCC 7120)
C:Species: Nostoc sp. PCC 7120
A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120
C:Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 09-Dec-2002
C:Accession: AC1927
R:Kanakko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi, S.; Nakazaki, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S.
DNA Res. 8, 205-213, 2001
A:Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Anabaena
A:Reference number: AB1807; MUID:21595285; PMID:11759840
A:Accession: AC1927
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-669 <KUR>
A:Cross-references: GB:BA000019; PIDN:BA072923.1; PID:g17130312; GSPDB:GN00179
A:Experimental source: strain PCC 7120
C:Genetics:
A:Gene: all0966

Query Match
Best Local Similarity 51.5%; Score 51; DB 2; Length 689;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 4 WKPMWPMW 12
DB 141 WMMGWPMW 149

RESULT 8
I38935
bone morphogenetic protein receptor II precursor - human
N:Alternate names: activin receptor-like kinase type II; bone morphogenetic protein 4 re
N:Contains: protein kinase (EC 2.7.1.37)
C:Species: Homo sapiens (man)
C:Date: 16-Feb-1996 #sequence_revision 16-Feb-1996 #text_change 24-Sep-1999
C:Accession: I38935; I55438; I37209
R:Kawabata, M.; Chytil, A.; Moses, H.L.
J. Biol. Chem. 270, 5625-5630, 1995
A:Title: Cloning of a novel type II serine/threonine kinase receptor through interaction
A:Reference number: A55947; MUID:95197572; PMID:7890683
A:Accession: I38935
A:Molecule type: mRNA
A:Residues: 1-1038 <KAW>
A:Cross-references: EMBL:U20165; NID:g704361; PIDN:AAC50105.1; PID:g704362
R:Nohno, T.; Ishikawa, T.; Saito, T.; Hosokawa, K.; Noji, S.; Wolsting, D.H.; Rosenbaum,
J. Biol. Chem. 270, 22522-22526, 1995
A:Title: Identification of a human type II receptor for bone morphogenetic protein-4 the
A:Reference number: I55438; MUID:95403457; PMID:7673243
A:Accession: I55438
A:Status: nucleic acid sequence not shown; translation not shown; translated from GB/EMF
A:Molecule type: mRNA
A:Residues: 1-1038 <NOH>
A:Cross-references: GB:D50516; NID:807712; PIDN:BA09094.1; PID:807713
R:Rosenzweig, B.L.; Imamura, T.; Okadome, T.; Cox, G.N.; Yamashita, H.; ten Dijke, P.; H
Proc. Natl. Acad. Sci. U.S.A. 92, 7632-7636, 1995
A:Title: Cloning and characterization of a human type II receptor for bone morphogenetic
A:Reference number: I37209; MUID:95372334; PMID:7644468
A:Accession: I37209
A:Status: nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-827; R', 829-1038 <ROS>
A:Cross-references: EMBL:Z48923; NID:g1009409; PIDN:CA08759.1; PID:g1009410
C:Genetics:
A:Gene: GDB:BMPR2; BRK-3; T-ALK; BMPR3; BMPR-II
A:Cross-references: GDB:642243; OMIM:600799
A:Map position: 20pter-20qter
C:Superfamily: unassigned Ser/Thr or Tyr-specific protein kinases; protein kinase homolo
C:Keywords: ATP; glycoprotein; phosphotransferase; receptor; transmembrane protein
F:1-26/Domain: signal sequence #status predicted <SIG>
F:27-1038/Product: bone morphogenetic protein receptor II #status predicted <MAT>

```

```

F:27-150/Domain: extracellular #status predicted <EXT>
F:151-170/Domain: transmembrane #status predicted <TRM>
F:201-508/Domain: protein kinase homology <KIN>
F:209-217/Region: protein kinase ATP-binding motif
F:55,110,126/Binding site: carbohydrate (asn) (covalent) #status predicted

Query Match
Best Local Similarity 51.5%; Score 51; DB 2; Length 1038;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3 PKMKPMWPMW 11
DB 8 PMKPMWPMW 16

RESULT 9
T28234
ORF MSV076 probable spheroidin - Melanoplus sanguinipes entomopoxvirus
C:Species: Melanoplus sanguinipes entomopoxvirus
C:Date: 21-Jan-2000 #sequence_revision 21-Jan-2000 #text_change 21-Jul-2000
C:Accession: T28234
R:Alfonso, C.L.; Tulman, E.R.; Lu, Z.; Oma, E.; Kutish, G.F.; Rock, D.L.
J. Virol. 73, 533-552, 1999
A:Title: The genome of Melanoplus sanguinipes entomopoxvirus.
A:Reference number: Z20484; MUID:99102612; PMID:9847359
A:Accession: T28234
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: DNA
A:Residues: 1-970 <AF0>
A:Cross-references: EMBL:AF063866; NID:g4049647; PIDN:AAC97813.1; PID:g4049853
C:Genetics:
A:Note: MSV076

Query Match
Best Local Similarity 51.0%; Score 50.5; DB 2; Length 970;
Matches 8; Conservative 3; Mismatches 2; Indels 1; Gaps 1;

QY 1 ILPMKPMW-PMW 13
DB 838 ILPMKPMWPMW 851

RESULT 10
B72392
hypothetical protein - Thermotoga maritima (strain MSB8)
C:Species: Thermotoga maritima
C:Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 21-Jul-2000.
C:Accession: B72392
R:Nelson, K.E.; Clayton, R.A.; Gill, S.R.; Gwin, M.L.; Dodson, R.J.; Haft, D.H.; Hic
Garrett, M.M.; Stewart, A.M.; Cotton, M.D.; Pratt, M.S.; Phillips, C.A.; Richardson,
C.M.
Nature 399, 323-329, 1999
A:Title: Evidence for lateral gene transfer between Archaea and Bacteria from genome
A:Reference number: A72200; MUID:99287316; PMID:10360571
A:Accession: B72392
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-83 <ARN>
A:Cross-references: GB:AE001713; GB:AE000512; NID:g4980809; PIDN:AAD35403.1; PID:g498
A:Experimental source: strain MSB8
C:Genetics:
A:Gene: TM0315

Query Match
Best Local Similarity 50.5%; Score 50; DB 2; Length 83;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4 WKPMWPMW 11
DB 7 WMMGWPMW 14

RESULT 11

```

G95922  
 probable glycosyltransferase protein Smb21068 [imported] - Sinorhizobium meliloti (strain  
 C:Species: Sinorhizobium meliloti  
 C:Date: 24-Aug-2001 #sequence.revision 24-Aug-2001 #text.change 30-Sep-2001  
 C:Accession: G95922  
 R:Finan, T.M.; Weidner, S.; Wong, K.; Buhmester, J.; Chain, P.; Vorholter, F.J.; Hernat  
 Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001  
 A:Title: The complete sequence of the 1,683-kb PSymb megaplasmid from the N2-fixing endo  
 A:Reference number: A95842; MUID:21396508; PMID:11481431  
 A:Accession: G95922  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-337 <KOR>  
 A:Cross-references: GB:AL591985; PIDN:CAC49047.1; PID:g15140532; GSPDB:GN00167  
 A:Experimental source: strain 1021, megaplasmid PSymb  
 R:Gallbert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.; Barloy-Hubler,  
 P.; Chain, P.; Cowie, A.; Davis, K.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.;  
 L.; Hyman, R.W.; Jones, T.  
 Science 293, 668-672, 2001  
 A:Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.; Lelaure,  
 hebanlt, P.; Vandenbol, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.  
 A:Title: The composite genome of the legume symbiont Sinorhizobium meliloti.  
 A:Reference number: A96039; MUID:21368234; PMID:11474104  
 A:Contents: annotation  
 C:Genetics:  
 A:Gene: Smb21068  
 A:Genome: plasmid

Query Match	50.5%;	Score 50;	DB 2;	Length 337;
Best Local Similarity	66.7%;	Pred. No. 19;		
Matches	6; Conservative	0; Mismatches	3; Indels	0; Gaps

OY 3 PPKPMPMP 11  
 11 11111  
 Db 262 PPKPMPMP 270

RESULT 12  
 J07071  
 ferredoxin-NADP reductase (EC 1.18.1.2), long form precursor - bovine  
 N:Alternate names: adrenodoxin reductase  
 C:Species: Bos primigenius taurus (cattle)  
 C:Date: 14-Jul-1994 #sequence.revision 18-Oct-1996 #text.change 03-Jun-2002  
 C:Accession: J07071; J07079; J03090; S03558; P50003; A29604; S52100  
 R:Yakata, Y.; Sagara, Y.; Kono, A.; Sekimizu, K.; Horiuchi, T.  
 Biol. Pharm. Bull. 16, 1200-1206, 1993  
 A:Title: Gene structure of bovine adrenodoxin reductase.  
 A:Reference number: J07071; MUID:94177140; PMID:8130767  
 A:Accession: J07071  
 A:Molecule type: DNA  
 A:Residues: 1-498 <TAK>  
 A:Cross-references: GB:D83475; NID:g1199916; PIDN:BA011921.1; PID:g4521308  
 A:Experimental source: adrenal cortex  
 A:Note: the authors translated the codon GNC for residue 205 as Gly  
 R:Sagara, Y.; Yakata, Y.; Miyata, T.; Hara, T.; Horiuchi, T.  
 J. Biochem. 102, 1333-1336, 1987  
 A:Title: Cloning and sequence analysis of adrenodoxin reductase cDNA from bovine adrenal  
 A:Reference number: J07079; MUID:88198050; PMID:3448086  
 A:Accession: J07079  
 A:Molecule type: mRNA  
 A:Residues: 1-204 211-498 <SAG>  
 A:Cross-references: GB:D00211; NID:g217433; PIDN:BA00150.1; PID:g217434  
 A:Note: the deduced sequence is partially confirmed by amino acid sequencing of 15 isolat  
 R:Sagara, Y.  
 submitted to DBJ, September 1989  
 A:Reference number: J50390  
 A:Contents: revision, insertion of residues 205-210  
 A:Accession: J50390  
 A:Molecule type: mRNA  
 A:Residues: 56-498 <SA2>  
 R:Hannuoglu, I.; Gultinger, T.  
 Eur. J. Biochem. 180, 479-484, 1989  
 A:Title: cDNA sequence of adrenodoxin reductase. Identification of NADP-binding sites in

A:Reference number: S03558; MUID:89170752; PMID:2924777  
 A:Accession: S03558  
 A:Molecule type: mRNA  
 A:Residues: 155-204, 211-498 <HAN>  
 A:Cross-references: EMBL:X13736; NID:g65; PIDN:CAA32002.1; PID:g833776  
 A:Note: 405-Ser was also found  
 R:Hamamoto, I.; Kurokouchi, K.; Tanaka, S.; Ichikawa, Y.  
 Biochim. Biophys. Acta 953, 207-213, 1988.  
 A:Title: Adrenoferradoxin-binding peptide of NADPH-adrenoferradoxin reductase.  
 A:Reference number: P50003; MUID:88184054; PMID:3355838  
 A:Accession: P50003  
 A:Molecule type: protein  
 A:Residues: 33-41, 'S', 43-62, 260-283, 'TW', 496-498 <HAN>  
 A:Note: A cyanogen bromide peptide binds to adrenoferradoxin  
 R:Nonaka, Y.; Murakami, H.; Yabasaki, Y.; Kuramitsu, S.; Kagamiyama, H.; Yamano, T.;  
 Biochem. Biophys. Res. Commun. 145, 1239-1247, 1987  
 A:Title: Molecular cloning and sequence analysis of full-length cDNA for mRNA of adre  
 A:Reference number: A29604; MUID:87270696; PMID:3038094  
 A:Accession: A29604  
 A:Molecule type: mRNA  
 A:Residues: 1-76, 'R', 78-80, 'VWLAATTPSRML', 95-123, 'RVYRLT', 129-204, 211-273, 'R', 275-3  
 A:Cross-references: GB:M17029; NID:g162628; PIDN:AAA30362.1; PID:g162629  
 A:Experimental source: adrenal cortex  
 R:Wabuton, R.J.; Seybert, D.W.  
 Biochim. Biophys. Acta 1246, 39-46, 1995  
 A:Title: Structural and functional characterization of bovine adrenodoxin reductase b  
 A:Reference number: S52100; MUID:95110846; PMID:7811729  
 A:Accession: S52100  
 A:Status: preliminary  
 A:Molecule type: protein  
 A:Residues: 'X', 34-41, 'X', 43-48, 'X', 50-51, 304-306, 'X', 308-309, 'X', 311-326 <MAR>  
 C:Comment: Ferradoxin-NADP+ reductase is localized in the matrix of adrenal cortex mi  
 erredoxin-NADP+ reductase, adrenodoxin and two forms of cytochrome P-450.  
 C:Genetics:  
 A:Introns: 27/1; 59/3; 91/3; 132/3; 170/3; 204/3; 246/3; 275/1; 341/3; 399/1; 456/1  
 C:Function:  
 A:Description: catalyzes the reversible reduction of NADP+ by reduced ferredoxin or r  
 C:Superfamily: human ferredoxin-NADP+ reductase  
 C:Keywords: alternative splicing; flavoprotein; mitochondrion; monomer; NADP; oxidore  
 F:1-32/Domains: transit peptide (mitochondrion) #status predicted <S16>  
 F:33-498/Product: ferredoxin-NADP+ reductase, long form #status predicted <MAR>  
 F:33-204, 211-498/Product: ferredoxin-NADP+ reductase, short form #status experimental  
 F:40-70/Region: beta-alpha-beta FAD nucleotide-binding fold  
 F:180-190/Region: NADP binding #status predicted  
 F:281/Binding site: substrate (lys) #status experimental

Query Match	50.5%;	Score 50;	DB 1;	Length 498;
Best Local Similarity	66.7%;	Pred. No. 28;		
Matches	6; Conservative	0; Mismatches	3; Indels	0; Gaps

OY 3 PPKPMPMP 11  
 11 11111  
 Db 3 PPKPMPMP 11

RESULT 13  
 T03562  
 conserved hypothetical protein - Rhodobacter capsulatus  
 C:Species: Rhodobacter capsulatus  
 C:Date: 24-Mar-1999 #sequence.revision 24-Mar-1999 #text.change 02-Aug-2002  
 C:Accession: T03562  
 R:Vilek, C.; Paces, V.; Maltsev, N.; Paces, J.; Haselkorn, R.; Fongstein, M.  
 Proc. Natl. Acad. Sci. U.S.A. 94, 9384-9388, 1997  
 A:Title: Sequence of a 189-kb segment of the chromosome of Rhodobacter capsulatus SB1  
 A:Reference number: Z14953; MUID:97404404; PMID:9256491  
 A:Accession: T03562  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-296 <VILC>  
 A:Cross-references: EMBL:AF010496; NID:g3128256; PIDN:AAC16215.1; PID:g3128363  
 C:Genetics:  
 A:Map position: 1  
 C:Superfamily: hypothetical protein yded

Query Match 50.0%; Score 49.5; DB 2; Length 296;  
 Best Local Similarity 50.0%; Pred. No. 20;  
 Matches 9; Conservative 3; Mismatches 1; Indels 5; Gaps 2;

OY 1 ILPKWMPW---WP-WRR 13  
 :||: ||| ||: ||  
 Db 52 LLPFAPWPLRDMPLYRR 69

## RESULT 14

A56547  
 sex-peptide precursor - Drosophila suzukii  
 N:Alternate names: male accessory gland peptide  
 C:Species: Drosophila suzukii  
 C:Date: 21-Jul-1995 #sequence\_revision 21-Jul-1995 #text\_change 21-Jul-2000  
 C:Accession: A56547; B56547  
 R:Schmidt, T.; Choiflat, Y.; Schneider, M.; Hunziker, P.; Fuyama, Y.; Kubli, E.  
 Insect Biochem. Mol. Biol. 23, 571-579, 1993  
 A:Title: Drosophila suzukii contains a peptide homologous to the Drosophila melanogaster  
 A:Reference number: A56547; MUID:93357785; PMID:8353518  
 A:Accession: A56547  
 A:Molecule type: DNA  
 A:Residues: 1-60 <SCH>  
 A:Cross-references: GB:S64573; NID:9409350; PIDN:AAB27872.2; PID:97548732  
 A:Note: sequence modified after extraction from NCBI backbone  
 A:Note: authors translated the codon TGC for residue 12 as Trp  
 A:Note: sequence extracted from NCBI backbone (NCBIN:136396)  
 A:Accession: B56547  
 A:Molecule type: protein  
 A:Residues: 20-60 <SC2>  
 A:Note: sequence modified after extraction from NCBI backbone  
 C:Genetics:  
 A:Gene: FLYBase:DsuZ/SP  
 A:Cross-references: FLYBase:FBgn0012991  
 A:Introns: 44/1  
 C:Keywords: neuropeptide  
 F:1-19/Domain: signal sequence #status predicted <SIG>  
 F:20-60/Product: sex-peptide #status experimental <MAT>

Query Match 49.5%; Score 49; DB 2; Length 60;  
 Best Local Similarity 50.0%; Pred. No. 4.8;  
 Matches 7; Conservative 1; Mismatches 2; Indels 4; Gaps 1;

OY 4 WKMPW---WPPRR 13  
 |:||| ||| |  
 Db 20 WEPWPKKKPPWR 33

## RESULT 15

E84631  
 probable serine carboxypeptidase II [Imported] - Arabidopsis thaliana  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C:Date: 02-Feb-2001 #sequence\_revision 02-Feb-2001 #text\_change 16-Feb-2001  
 C:Accession: E84631  
 R:Lin, X.; Kaul, S.; Rounsley, S.D.; Snea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.;  
 M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; Vanaken, S.E.; Umayam, L.; Tallon, L.;  
 euss, D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter, J.  
 Nature 402, 761-768, 1999  
 A:Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.  
 A:Reference number: A84420; MUID:20083487; PMID:10617197  
 A:Accession: E84631  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-425 <STO>  
 A:Cross-references: GB:AE002093; NID:g3738328; PIDN:AAC63669.1; GSPDB:GNO0139  
 C:Genetics:  
 A:Gene: AL2924010  
 A:Map position: 2  
 C:Superfamily: serine carboxypeptidase

Query Match 49.5%; Score 49; DB 2; Length 425;  
 Best Local Similarity 70.0%; Pred. No. 32;

Matches 7; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 OY 2 LPKWPMPW 11  
 ||| |||:  
 Db 363 LPVKTPWYPM 372

Search completed: October 2, 2003, 10:04:46  
 Job time : 42 secs

**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:57:07 ; Search time 25 seconds

(without alignments)  
24.454 Million cell updates/sec

Title: US-09-444-281-85

Sequence: 99  
1 ILPMKMPMPMPMR 13

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database : SwissProt\_41.\*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	99	100.0	144	INCC_BOVIN	P33046 bos taurus
2	54	54.5	1173	VGL2_CVH22	P15423 human coron
3	53	53.5	327	Y013_NPVAC	P41423 ontograpa
4	51	51.5	1038	BMR2_HUMAN	013873 homo sapien
5	50	50.5	55	ATP8_CORN	09416 corythaxol
6	50	50.5	492	ADRO_BOVIN	P08165 bos taurus
7	48	48.5	55	ATP8_PELSU	079674 pelomedusa
8	47.5	48.0	279	ELO1_HUMAN	091660 homo sapien
9	47.5	48.0	279	ELO1_MOUSE	091660 mus musculu
10	47	47.5	55	ATP8_GADMO	P15596 gadus morhu
11	47	47.5	55	ATP8_ONCHY	P48179 oncorhynch
12	47	47.5	55	ATP8_PRODO	033416 protocerus
13	47	47.5	55	ATP8_SALAL	094273 salvelinus
14	47	47.5	55	ATP8_SALFO	094273 salvelinus
15	47	47.5	55	ATP8_SCYCA	079403 scyllorhinu
16	47	47.5	55	ATP8_SQUAC	094250 squalus aca
17	47	47.5	55	ATP8_VIRAL	094251 viroo altit
18	47	47.5	55	ATP8_XENLA	P03931 xenopus lae
19	47	47.5	253	Y945_MYCTU	P13164 mycobacteri
20	47	47.5	1112	CN3B_HUMAN	Q13370 homo sapien
21	46	46.5	55	ATP8_CHICK	P14093 gallus gall
22	46	46.5	55	ATP8_ANAPL	P50655 anas platyr
23	46	46.5	55	ATP8_AYTAM	094255 aythya amer
24	46	46.5	55	ATP8_CHAPE	094259 chaetura pe
25	46	46.5	55	ATP8_COLPA	094257 colymba p
26	46	46.5	55	ATP8_CORCR	094257 corythaeola
27	46	46.5	55	ATP8_COTJA	P50682 coturnix co
28	46	46.5	55	ATP8_IATCA	003168 latimeria c
29	46	46.5	55	ATP8_LOXNO	094251 loxigilla n
30	46	46.5	55	ATP8_MOSHO	094258 musophaga v
31	46	46.5	55	ATP8_OPIHO	094258 opisthocoma
32	46	46.5	55	ATP8_RHEAM	079396 rhea americ
33	46	46.5	55	ATP8_STRCA	021401 struthio ca

## ALIGNMENTS

RESULT 1	ID	INCC_BOVIN	STANDARD:	PRT:	144 AA.
AC	P33046;				
DT	01-OCT-1993 (Rel. 27, Created)				
DT	01-OCT-1993 (Rel. 27, Last sequence update)				
DE	15-SEP-2003 (Rel. 42, Last annotation update)				
DE	Indolicidin precursor.				
OS	Bos taurus (Bovine).				
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;				
OC	Bovidae; Bovinae; Bos.				
OX	NCBI_TaxID=9913;				
RN	[1]				
RP	SEQUENCE FROM N.A.				
RC	TISSUE=Bone marrow;				
RA	MEDLINE=92392368; PubMed=1520337;				
RA	del Sal G., Storici P., Schneider C., Romeo D., Zanetti M.;				
RT	"CDNA cloning of the neutrophil bactericidal peptide indolicidin.";				
RL	Biochem. Biophys. Res. Commun. 187:467-472(1992).				
RN	[2]				
RP	SEQUENCE OF 131-143.				
RC	TISSUE=Neutrophils;				
RA	MEDLINE=92165771; PubMed=1537821;				
RA	Selsted M.E., Novotny M.J., Morris W.L., Tang Y.-Q., Smith W.;				
RT	Cullor J.S.;				
RL	"Indolicidin, a novel bactericidal tridecapeptide amide from				
RL	neutrophils.";				
RL	J. Biol. Chem. 267:4292-4295(1992).				
CC	- FUNCTION: POTENT MICROBICIDAL ACTIVITY, ACTIVE AGAINST				
CC	STAPHYLOCOCCUS AUREUS AND ESCHERICHIA COLI.				
CC	- TISSUE SPECIFICITY: LARGE GRANULES OF NEUTROPHILS.				
CC	- PTM: ELASTASE MIGHT BE RESPONSIBLE FOR ITS MATURATION.				
CC	- SIMILARITY: BELONGS TO THE CATHELICIDIN FAMILY.				
CC	-----				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -				
CC	the European Bioinformatics Institute. There are no restrictions on its				
CC	use by non-profit institutions as long as its content is in no way				
CC	modified and this statement is not removed. Usage by and for commercial				
CC	entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a>				
CC	or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ).				
CC	-----				
DR	EMBL; X67340; CAA47755.1; -				
DR	PIR; J01222; J01222.				
DR	PDB; 1G89; 17-JAN-01.				
DR	PDB; 1G8C; 17-JAN-01.				
DR	PDB; 1HRI; 31-DEC-02.				
DR	InterPro: IPR001894; Cathelicidin.				
DR	Pfam: PF00666; Cathelicidin; 1.				
DR	ProDom: PD001838; Cathelicidin; 1.				
DR	PROSITE: PS00946; CATHELICIDIN_1; 1.				
DR	PROSITE: PS00947; CATHELICIDIN_2; 1.				
KW	Antibiotic; Amidation; Signal; Pyrrolidone carboxylic acid;				
FT	3D-structure. 1 29 POTENTIAL.				

FT PROPEP 30 130  
 FT PEPTIDE 131 143 INDOLICIDIN.  
 FT MOD\_RES 30 30 PYRROLIDONE CARBOXYLIC ACID (BY  
 FT MOD\_RES 85 96 SIMILARITY).  
 FT DISULFID 107 124 BY SIMILARITY.  
 FT MOD\_RES 143 143 AMIDATION (G-144 PROVIDE AMIDE GROUP).  
 SQ SEQUENCE 144 AA: 16479 MW: E3B1GBE55C09911 CMC64.  
 Query Match 100.0%; Score 99; DB 1; Length 144;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ILPWKWPMPWRR 13  
 DB 131 ILPWKWPMPWRR 143  
 RESULT 2  
 VGL2\_CVH22 STANDARD: PRT: 1173 AA.  
 AC P15423; P89344; P89343; P89344; Q66174; Q990M1; Q990M2; Q990M3;  
 AC Q990M4;  
 DT 01-APR-1990 (Rel. 14, Created)  
 DT 01-APR-1990 (Rel. 14, Last sequence update)  
 DT 15-SEP-2003 (Rel. 42, Last annotation update)  
 DE E2 glycoprotein precursor (Spike glycoprotein) (Peplomer protein).  
 GN S.  
 OS Human coronavirus (strain 229E) (HCoV-229E).  
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
 OC Coronaviridae; Coronavirus.  
 NC NCBI\_TaxID=11137;  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE-90264837; PubMed-2345367;  
 RA Raabe T., Schelle-prinz B., Siddell S.G.;  
 RT "Nucleotide sequence of the gene encoding the spike glycoprotein of  
 human coronavirus HCoV 229E.";  
 RL J. Gen. Virol. 71:1065-1073(1990).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE-21262210; PubMed-11369870;  
 RA Thiel V., Herold J., Schelle B., Siddell S.G.;  
 RT "Infectious RNA transcribed in vitro from a cDNA copy of the human  
 coronavirus genome cloned in vaccinia virus.";  
 RL J. Gen. Virol. 82:1273-1281(2001).  
 RN [3]  
 RP SEQUENCE OF 98-1113 FROM N.A., AND VARIANTS.  
 RC STRAIN=Isolate RW Stock, Isolate P100E, Isolate P11A, and  
 RC Isolate P11B;  
 RA Bonavia A., Holmes K.V.;  
 RT "Viral and cellular changes in a human cell line persistently infected  
 with human coronavirus HCoV-229E.";  
 RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE OF 98-1113 FROM N.A., AND VARIANTS.  
 RC STRAIN=Isolate ATCC VR-74, Isolate A162, and Isolate LRI 281;  
 RX MEDLINE-99086140; PubMed-9870593;  
 RA Hays J.P., Myint S.H.;  
 RT "PCR sequencing of the spike genes of geographically and  
 RT chronologically distinct human coronaviruses 229E.";  
 RL J. Virol. Methods 75:179-193(1998).  
 RN [5]  
 FT SEQUENCE OF 1159-1173 FROM N.A.  
 RX MEDLINE-8936667; PubMed-2701946;  
 RA Raabe T., Siddell S.;  
 RT "Nucleotide sequence of the human coronavirus HCV 229E mRNA 4 and mRNA  
 RT 5 unique regions.";  
 RL Nucleic Acids Res. 17:6387-6387(1989).  
 RN [6]  
 RP INTERACTION WITH ANPEP.  
 RX MEDLINE-2440020; PubMed-1255191;  
 RA Bonavia A., Zelus B.D., Wentworth D.E., Talbot P.J., Holmes K.V.;

RT "Identification of a receptor-binding domain of the spike glycoprotein  
 RT of human coronavirus HCoV-229E.";  
 RL J. Virol. 77:2530-2538(2003).  
 RN [7]  
 RP INTERACTION WITH ANPEP.  
 RX MEDLINE-22521439; PubMed-12634402;  
 RA Breslin J.J., Mork I., Smith M.K., Vogel L.K., Hemmila E.M.,  
 RA Bonavia A., Talbot P.J., Sjoestrom H., Noren O., Holmes K.V.;  
 RT "Human coronavirus 229E: receptor binding domain and neutralization, by  
 RT soluble receptor at 37 degrees C.";  
 RL J. Virol. 77:4435-4438(2003).  
 RN [8]  
 RP REVIEW.  
 RX MEDLINE-21109095; PubMed-11162792;  
 RA Gallagher T.M., Buchmeier M.J.;  
 RT "Coronavirus spike proteins in viral entry and pathogenesis.";  
 RL Virology 279:371-374(2001).  
 CC -I- FUNCTION: Structural protein that makes spikes at the surface of  
 CC the virus. Determines enteropathogenicity and virulence of the  
 CC virus. Initiates infection by specifically recognizing and binding  
 CC the human aminopeptidase ANPEP receptor. Its association with  
 CC ANPEP may lead to its conformational change that triggers fusion  
 CC between viral and host cellular membrane.  
 CC -I- SUBUNIT: Homotrimer. During virus morphogenesis, it is found in a  
 CC complex with M and HE proteins (By similarity). Interacts with  
 CC ANPEP.  
 CC -I- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -I- DOMAIN: The spike S1 domain displays the specificity for the host  
 CC receptor.  
 CC -I- DOMAIN: The leucine zipper-like heptad repeats may mediate the  
 CC fusion of viral and cellular membranes.  
 CC -I- POLYMORPHISM: The strong variation of the different  
 CC strains may affect the virulence of the virus.  
 CC -I- MISCELLANEOUS: In contrast to serogroup 2, E2 glycoprotein protein  
 CC from serogroup 1 is not cleaved.  
 CC -I- SIMILARITY: Contains 1 spike S1 domain.  
 CC -I- SIMILARITY: Contains 1 spike S2 domain.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: X16816; CA34723.1; -  
 CC EMBL: AF304460; AAG4892.1; -  
 CC EMBL: AF344186; AAK32188.1; -  
 CC EMBL: AF344187; AAK32189.1; -  
 CC EMBL: AF344188; AAK32190.1; -  
 CC EMBL: AF344189; AAK32191.1; -  
 CC EMBL: Y09923; CA271056.1; -  
 CC EMBL: Y10051; CA271146.1; -  
 CC EMBL: Y10052; CA271147.1; -  
 CC EMBL: X15654; CA33680.1; -  
 CC PIR: A34766; VGIRHC.  
 CC InterPro: IPR002551; Corona\_S1.  
 CC InterPro: IPR002552; Corona\_S2.  
 CC Pfam: PF01600; Corona\_S1.  
 CC Pfam: PF01601; Corona\_S2.  
 CC Virulence: Glycoprotein; Envelope protein; Transmembrane; Signal;  
 CC Coiled coil.  
 CC SIGNAL 1 15  
 CC CHAIN 16 1173  
 CC DOMAIN 16 1115  
 CC TRANSMEM 1116 1135  
 CC DOMAIN 1136 1173  
 CC DOMAIN 32 536  
 CC DOMAIN 417 547  
 CC DOMAIN 537 1171  
 CC DOMAIN 1054 1103  
 CC DOMAIN 1067 1102  
 CC E2 GLYCOPROTEIN.  
 CC EXTRACELLULAR (POTENTIAL).  
 CC POTENTIAL.  
 CC CYTOPLASMIC (POTENTIAL).  
 CC SPIKE S1.  
 CC INTERACTION WITH ANPEP.  
 CC SPIKE S2.  
 CC COILED COIL (POTENTIAL).  
 CC LEUCINE ZIPPER-LIKE HEPTAD REPEATS.

FT	DOMAIN	1136	1157	CYS-RICH
FT	CARBOHYD	223	62	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	98	98	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	147	147	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	171	171	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	176	176	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	220	220	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	243	243	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	326	326	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	333	333	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	440	440	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	464	464	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	518	518	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	538	538	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	542	542	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	568	568	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	581	581	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	587	587	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	663	663	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	671	671	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	930	930	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1015	1015	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1020	1020	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1037	1037	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1049	1049	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1061	1061	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1066	1066	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1076	1076	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1082	1082	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	1096	1096	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	CARBOHYD	98	98	N-LINKED (GLCNAC . .) (POTENTIAL)
FT	VARIANT	120	120	N -> S (in isolate LRI 281)
FT	VARIANT	127	128	N -> I (in isolate LRI 281)
FT	VARIANT	176	176	LR -> IS (in isolate A162)
FT	VARIANT	210	210	LR -> T (in isolate P100E)
FT	VARIANT	223	223	T -> S (in isolate A162)
FT	VARIANT	228	229	T -> N (in isolate A162)
FT	VARIANT	230	230	DF -> V (in isolate A162)
FT	VARIANT	230	230	C -> L (in isolate LRI 281)
FT	VARIANT	230	230	C -> F (in isolates RW Stock, P11A, P11B P100E and ATCC VR-74)
FT	VARIANT	248	248	S -> A (in isolate A162)
FT	VARIANT	270	270	D -> Y (in isolate P100E)
FT	VARIANT	295	295	V -> A (in isolate LRI 281)
FT	VARIANT	300	300	T -> M (in isolate P100E)
FT	VARIANT	307	307	D -> N (in isolate A162)
FT	VARIANT	310	311	PO -> LR (in isolate A162)
FT	VARIANT	314	324	GGGCFNCYPRAG -> VGRGRCNRPAY (in isolate A162)
FT	VARIANT	336	336	K -> N (in isolate LRI 281)
FT	VARIANT	349	358	KYAVAVANG -> GPVGKFPD (in isolate A162)
FT	VARIANT	401	401	V -> M (in isolate A162)
FT	VARIANT	404	411	MAWSKYT -> LANINSHN (in isolate A162)
FT	VARIANT	414	414	S -> T (in isolate P100E)
FT	VARIANT	424	424	G -> V (in isolate A162)
FT	VARIANT	430	430	Q -> K (in isolate A162)
FT	VARIANT	441	441	V -> A (in isolate LRI 281)
FT	VARIANT	444	444	D -> N (in isolate A162)
FT	VARIANT	462	462	V -> I (in isolate A162)
FT	VARIANT	481	481	L -> V (in isolate A162)
FT	VARIANT	488	488	K -> N (in isolate A162)
FT	VARIANT	530	530	K -> N (in isolate A162)
FT	VARIANT	577	577	I -> T (in isolate A162)
FT	VARIANT	578	578	V -> G (in isolate P11B)
FT	VARIANT	590	590	T -> I (in isolate P100E)
FT	VARIANT	642	642	R -> M (in isolate A162)
FT	VARIANT	681	681	T -> R (in isolate A162)
FT	VARIANT	700	700	L -> I (in isolates RW Stock, P11A, P11B and P100E)
FT	VARIANT	711	711	D -> N (in isolate LRI 281)
FT	VARIANT	714	714	K -> N (in isolates RW Stock, P11A, P11B and P100E)
FT	VARIANT	765	765	V -> A (in isolate A162)

FT	VARIANT	775	775	A -> S (in isolate A162).
	Query Match		54.5%;	Score 54; DB 1; Length 1173;
	Best Local Similarity		85.7%;	Pred. No. 9.9;
	Matches	6;	Conservative	0; Mismatches 1; Indels 0; Gaps 0;
OY		5	KMPMPW 11	
		111111		
Db		1113	KMPMPW 1119	
RESULT 3				
ID	Y013_NPVAC	STANDARD;	PRT;	327 AA.
AC	P41423;			
DT	01-NOV-1995 (Rel. 32, Created)			
DT	01-NOV-1995 (Rel. 32, Last sequence update)			
DT	01-NOV-1997 (Rel. 35, Last annotation update)			
DE	Hypothetical 38.7 Kda protein in PK1-LEF1 intergenic region.			
OS	Autographa californica nuclear polyhedrosis virus (AcMNPV).			
OC	Viruses; dsDNA viruses, no RNA stage; Baculoviridae;			
CC	Nucleopolyhedrovirus.			
CC	NCBI_TaxID=46015;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	STRAIN=C6;			
RX	MEDLINE=94303173; PubMed=8030224;			
RA	Ayres M.D., Howard S.C., Kuzio J., Lopez-Ferber M., Possee R.D.;			
RT	"The complete DNA sequence of Autographa californica nuclear			
RT	polyhedrosis virus."			
RL	Virology 202;586-605(1994).			
RN	[2]			
RP	SEQUENCE OF 1-209 FROM N.A.			
RC	STRAIN=LI;			
RX	MEDLINE=93267802; PubMed=8497062;			
RA	Passarelli A.L., Miller L.K.;			
RT	"Identification and characterization of left-1, a baculovirus gene			
RT	involved in late and very late gene expression."			
RL	J. Virol. 67:3481-3488(1993).			
CC	-1- SIMILARITY: TO CORRESPONDING ORF IN OPMNPV.			
CC	-----			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (see <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a>			
CC	or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ).			
CC	-----			
DR	EMBL; L22858; AAA66643.1; -			
DR	EMBL; L09723; AAA46706.1; -			
KM	PIR: E72851; E72851.			
RY	Hypothetical protein.			
SO	SEQUENCE 327 AA; 38660 MW; 40494C1D62285171 CRC64;			
Query Match				
	Best Local Similarity	53.5%;	Score 53; DB 1; Length 327;	
	Matches	6; Conservative	1; Mismatches	4; Indels 0; Gaps 0;
OY		1	ILPKMKMPW 11	
		111111		
Db		1	MLSLMLNMMW 11	
RESULT 4				
ID	BMR2_HUMAN	STANDARD;	PRT;	1038 AA.
AC	BMR2_HUMAN			
DT	013873; 016569;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	16-OCT-2001 (Rel. 40, Last sequence update)			
DT	15-SEP-2003 (Rel. 42, Last annotation update)			
DE	Bone morphogenetic protein receptor type II precursor (EC 2.7.1.37)			
	(BMP type II receptor) (BMPRII).			

GN BMPR2 OR PPH1.  
 OS Homo sapiens (Human).  
 OC Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 OC NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Substantia nigra;  
 RA MEDLINE=9537234; PubMed=7644468;  
 RA Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H.,  
 RA ten Dijke P., Heidin C., Miyazono K.;  
 RT "Cloning and characterization of a human type II receptor for bone  
 RT morphogenetic proteins.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 92:7632-7636(1995).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Skin fibroblast;  
 RA MEDLINE=95403457; PubMed=7673243;  
 RA Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wosling D.H.,  
 RA Rosenbaum J.S.;  
 RT "Identification of a human type II receptor for bone morphogenetic  
 RT protein-4 that forms differential heteromeric complexes with bone  
 RT morphogenetic protein type I receptors.";  
 RL J. Biol. Chem. 270:22522-22526(1995).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC MEDLINE=95197572; PubMed=7890683;  
 RA Kawabata M., Chytil A., Moses H.L.;  
 RT "Cloning of a novel type II serine/threonine kinase receptor through  
 RT interaction with the type I transforming growth factor-beta  
 RT receptor.";  
 RL J. Biol. Chem. 270:5625-5630(1995).  
 RN [4]  
 RP VARIANTS PPH1 GLN-491 AND TRP-491.  
 RA MEDLINE=20395844; PubMed=10903931;  
 RA Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G.,  
 RA Kalachikov S., Cayanis E., Fischer S.G., Barst R.D., Hodge S.E.,  
 RA Knowles J.A.;  
 RT "Familial primary pulmonary hypertension (gene PPH1) is caused by  
 RT mutations in the bone morphogenetic protein receptor-II gene.";  
 RL Am. J. Hum. Genet. 67:737-744(2000).  
 RN [5]  
 RP VARIANTS PPH1 TYR-60; TYR-117 AND ARG-483.  
 RA MEDLINE=20473811; PubMed=11015450;  
 RA Thomson J.R., Machado R.D., Paucilio M.W., Morgan N.V., Humbert M.,  
 RA Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J.H.,  
 RA Wheeler L., Higgenbottom T., Gibbs J.S.R., Egan J., Crozier A.,  
 RA Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C.,  
 RA Nichols W.C.;  
 RT "Sporadic primary pulmonary hypertension is associated with germline  
 RT mutations of the gene encoding BMPR-II, a receptor member of the  
 RT TGF-beta family.";  
 RL J. Med. Genet. 37:741-745(2000).  
 RN [6]  
 RP VARIANTS PPH1 TRP-118; TYR-347 AND GLY-485.  
 RA MEDLINE=20428187; PubMed=10973234;  
 RA Lane K.B., Machado R.D., Paucilio M.W., Thomson J.R.,  
 RA Phillips J.A. IIR, Loyd J.E., Nichols W.C., Trembath R.C., Aldred M.,  
 RA Brannon C.A., Conneally P.M., Foroud T., Fretwell N., Gaddipati R.,  
 RA Koller D., Loyd E.J., Morgan N.V., Newman J.H., Prince M.A.,  
 RA Villalino Gueell C., Wheeler L.;  
 RT "Heterozygous germline mutations in BMPR2, encoding a TGF-beta  
 RT receptor, cause familial primary pulmonary hypertension.";  
 RL Nat. Genet. 26:81-84(2000).  
 RN [7]  
 RP VARIANTS PPH1 ARG-123; SER-123; ARG-420 AND THR-512, VARIANT ASP-224,  
 RP AND CHARACTERIZATION OF VARIANT PPH1 GLY-485.  
 RA MEDLINE=21065176; PubMed=11115378;  
 RA Machado R.D., Paucilio M.W., Thomson J.R., Lane K.B., Morgan N.V.,  
 RA Wheeler L., Phillips J.A. IIR, Newman J.H., Williams D., Galie N.,  
 RA Manes A., McNeill K., Yacoub M., Mikhail G., Rogers P., Corris P.,  
 RA Humbert M., Donnai D., Mattenson G., Tranahjerg L., Loyd J.E.,  
 RA Trembath R.C., Nichols W.C.;

RT "BMPR2 haploinsufficiency as the inherited molecular mechanism for  
 RT primary pulmonary hypertension.";  
 RL Am. J. Hum. Genet. 68:92-102(2001).  
 CC -1- FUNCTION: BINDS TO BMP-7, BMP-2 AND, LESS EFFICIENTLY, BMP-4.  
 CC BINDING IS WEAK BUT ENHANCED BY THE PRESENCE OF TYPE I RECEPTORS  
 CC FOR BMPS.  
 CC -1- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.  
 CC -1- SUBUNIT: HETERODIMERIZE WITH TYPE-I RECEPTORS.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN HEART AND LIVER.  
 CC -1- DISEASE: Defects in BMPR2 are the cause of primary pulmonary  
 CC hypertension (PPH1) [MIM:178600]; a rare autosomal dominant  
 CC disorder characterized by plexiform lesions of proliferating  
 CC endothelial cells in pulmonary arterioles. The lesions lead to  
 CC elevated pulmonary arterial pressure, right ventricular failure,  
 CC and death. The disease can occur from infancy throughout life and  
 CC it has a mean age at onset of 36 years. Penetrance is reduced.  
 CC Although familial PPH1 is rare, cases secondary to known  
 CC etiologies are more common and include those associated with the  
 CC appetite-suppressant drugs.  
 CC -1- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.  
 CC TGF-RECEPTOR SUBFAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 CC EMBL: 248923; CAA88759.1; -;  
 CC EMBL: D50516; BAA09094.1; -;  
 CC EMBL: U20165; AAC50105.1; -;  
 CC PIR: I38935; I38935.  
 CC GeneW: HGNC:1078; BMPR2.  
 CC MIM: 600799; -;  
 CC MIM: 178600; -;  
 CC GO: GO:0005887; C: Integral to plasma membrane; TAS.  
 CC GO: GO:0005515; F: protein binding activity; TAS.  
 CC GO: GO:0007178; P: transmembrane receptor protein serine/threo. . . ; TAS.  
 CC InterPro: IPR000472; Activin\_rec.  
 CC InterPro: IPR000719; Prot\_Kinase.  
 CC InterPro: IPR002290; Ser\_thr\_pkinase.  
 CC Pfam: PF01064; Activin\_rec1.  
 CC Pfam: PF00069; Pkinase; 1.  
 CC ProDom: PD000001; Prot\_kinase; 1.  
 CC PROSITE: PS00107; PROTEIN\_KINASE\_ATP; 1.  
 CC PROSITE: PS00108; PROTEIN\_KINASE\_ST; FALSE\_NEG.  
 CC PROSITE: PS50011; PROTEIN\_KINASE\_DOM; 1.  
 CC Receptor; Transferase; Serine/threonine-protein kinase; ATP-binding;  
 CC Transmembrane; Glycoprotein; Signal; Polymorphism; Disease mutation.  
 CC SIGNAL 1 26  
 CC CHAIN 27 1038  
 CC -----  
 CC BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE  
 CC II.  
 CC EXTRACELLULAR (POTENTIAL).  
 CC POTENTIAL.  
 CC CYTOPLASMIC (POTENTIAL).  
 CC PROTEIN KINASE.  
 CC ATP (BY SIMILARITY).  
 CC ATP (BY SIMILARITY).  
 CC BY SIMILARITY.  
 CC POLY-SER.  
 CC POLY-THR.  
 CC POLY-ASN.  
 CC N-LINKED (GLCNAc. . . ) (POTENTIAL).  
 CC N-LINKED (GLCNAc. . . ) (POTENTIAL).  
 CC N-LINKED (GLCNAc. . . ) (POTENTIAL).  
 CC C->Y (in PPH1).  
 CC /FTID=VAR\_013670.  
 CC C->Y (in PPH1).  
 CC /FTID=VAR\_013671.  
 CC C->W (in PPH1).  
 CC -----  
 CC VARIANT 118 118

```

FT  VARIANT 123 123 /FTID=VAR_013672.
FT  VARIANT 123 123 C -> R (in PPH1).
FT  VARIANT 123 123 /FTID=VAR_013673.
FT  VARIANT 224 224 C -> S (in PPH1).
FT  VARIANT 224 224 /FTID=VAR_013674.
FT  VARIANT 347 347 E -> D.
FT  VARIANT 347 347 /FTID=VAR_013675.
FT  VARIANT 420 420 C -> Y (in PPH1).
FT  VARIANT 420 420 /FTID=VAR_013676.
FT  VARIANT 483 483 C -> R (in PPH1).
FT  VARIANT 483 483 /FTID=VAR_013677.
FT  VARIANT 485 485 C -> R (in PPH1).
FT  VARIANT 485 485 /FTID=VAR_013678.
FT  VARIANT 491 491 D -> G (in PPH1; complete loss of
FT  VARIANT 491 491 function).
FT  VARIANT 491 491 /FTID=VAR_013679.
FT  VARIANT 491 491 R -> Q (in PPH1; sporadic).
FT  VARIANT 491 491 /FTID=VAR_013680.
FT  VARIANT 512 512 R -> W (in PPH1).
FT  VARIANT 512 512 /FTID=VAR_013681.
FT  VARIANT 519 519 K -> T (in PPH1).
FT  VARIANT 519 519 /FTID=VAR_013682.
FT  VARIANT 519 519 N -> R (in PPH1).
FT  VARIANT 519 519 /FTID=VAR_013683.
FT  VARIANT 828 828 G -> R (in REF. 1).
FT  VARIANT 828 828 /FTID=VAR_013684.
FT  VARIANT 1038 AA; 115201 MM; 1389923CE574B913 CRC64;

```

```

Query Match 51.5%; Score 51; DB 1; Length 1038;
Best Local Similarity 66.7%; Pred. No. 21;
Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy 3 PPKMPMPW 11
Db 8 PPKMPMPW 16

```

```

RESULT 5
ID ATP8 CORCN STANDARD; PRT; 55 AA.
AC Q9TB16;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
GN ATP8 OR ATP8.
OS Corythaeoides concolor (Grey go-away-bird).
OG Mitochondrion.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Aves; Neognathae; Musophagiformes; Musophagidae;
OC Corythaeoides.
OX NCBI_TaxID=103956;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99416451; PubMed=10486983;
RA Hughes J.M., Baker A.J.;
RT "Phylogenetic relationships of the enigmatic hoatzin (Opisthocomus
RT hoatzin) resolved using mitochondrial and nuclear gene sequences.";
RL Mol. Biol. Evol. 16:1300-1307(1999).
CC - FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC (CF0) SUBUNIT OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC - CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (in) = ADP + phosphate +
CC H(+) (out).
CC - SUBCELLULAR LOCATION: Membrane-bound.
CC - SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC
CC This SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb.ch/announce/
CC or send an email to license@isb-sib.ch).

```

```

DR EMBL: AF168039; AAD56467.1; -.
DR InterPro: IPR001421; ATPase_mlt.
DR Pfam: PF00895; ATP-synt_8; 1.
KW Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
SQ SEQUENCE 55 AA; 6485 MW; 973552DB0E918AD CRC64;

```

```

Query Match 50.5%; Score 50; DB 1; Length 55;
Best Local Similarity 85.7%; Pred. No. 2;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Oy 2 LPPKMPW 8
Db 48 LPPKMPW 54

```

```

RESULT 6
ID ADRO BOVIN STANDARD; PRT; 492 AA.
AC P08165; O95KN8;
DT 01-AUG-1988 (Rel. 08, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE NADPH:adrenodoxin oxidoreductase, mitochondrial precursor
DE (EC 1.18.1.2) (Adrenodoxin reductase) (AR) (ferredoxin-NADP(+)
DE reductase).
GN FDXR OR ADXR.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RX MEDLINE=94177140; PubMed=8130767;
RA Takata Y., Sagara Y., Kono A., Sekimizu K., Horikuchi T.;
RT "Gene structure of bovine adrenodoxin reductase.";
RL Biol. Pharm. Bull. 16:1200-1206(1993).
RN [2]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RX MEDLINE=88198050; PubMed=3448086;
RA Sagara Y., Takata Y., Miyata T., Hara T., Horikuchi T.;
RT "Cloning and sequence analysis of adrenodoxin reductase cDNA from
RT bovine adrenal cortex.";
RL J. Biochem. 102:1333-1336(1987).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=87270696; PubMed=3038094;
RA Nonaka Y., Murakami H., Yabusaki Y., Kuramitsu S., Kagamiyama H.;
RT "Molecular cloning and sequence analysis of full-length cDNA for mRNA
RT of adrenodoxin oxidoreductase from bovine adrenal cortex.";
RL Biochem. Biophys. Res. Commun. 145:1239-1247(1987).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=86062777; PubMed=3691502;
RA Hanukoglu I., Gutfinger T., Hanu M., Shively J.E.;
RT "Isolation of a cDNA for adrenodoxin reductase (ferredoxin-NADP+
RT reductase). Implications for mitochondrial cytochrome P-450 systems.";
RL Eur. J. Biochem. 169:449-455(1987).
RN [6]
RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 33-492.
RX TISSUE=Adrenal gland;
RX MEDLINE=99299392; PubMed=10369776;
RA Ziegler G.A., Vourhel C., Hanukoglu I., Schulz G.E.;

```

RT "The structure of adrenodoxin reductase of mitochondrial P450 systems:  
RT election transfer for steroid biosynthesis.";  
RL J. Mol. Biol. 289:981-990(1999).  
RP [7]  
RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS).  
RX MEDLINE=20455764; PubMed=10998235;  
RA Ziegler G.A., Schulz G.E.;  
RT "Crystal structures of adrenodoxin reductase in complex with NADP+ and  
RT NADPH suggesting a mechanism for the electron transfer of an enzyme  
RT family.";  
RL Biochemistry 39:10986-10995(2000).  
RN [8]  
RN X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF COMPLEX WITH ADRENODOXIN.  
RX MEDLINE=21264735; PubMed=11053423;  
RA Mueller J.J., Lapko A., Bourenkov G., Ruckpaul K., Heinemann U.;  
RT "Adrenodoxin reductase-adrenodoxin complex structure suggests electron  
RT transfer path in steroid biosynthesis.";  
RL J. Biol. Chem. 276:2786-2789(2001).  
CC -I- FUNCTION: SERVES AS THE FIRST ELECTRON TRANSFER PROTEIN IN ALL THE  
CC MITOCHONDRIAL P450 SYSTEMS, INCLUDING CHOLESTEROL SIDE CHAIN  
CC CLEAVAGE IN ALL STEROIDOGENIC TISSUES, STEROID 11-BETA  
CC HYDROXYLATION IN THE ADRENAL CORTEX, 25-OH-VITAMIN D3-24  
CC HYDROXYLATION IN THE KIDNEY, AND STEROL C-27 HYDROXYLATION IN THE  
CC LIVER.  
CC -I- CATALYTIC ACTIVITY: Reduced adrenodoxin + NADP(+) = oxidized  
CC adrenodoxin + NADPH.  
CC -I- COFACTOR: FAD.  
CC -I- PATHWAY: CHOLESTEROL SIDE-CHAIN-CLEAVAGE SYSTEM.  
CC -I- SUBUNIT: Monomer.  
CC -I- SUBCELLULAR LOCATION: Mitochondrial matrix.  
CC -I- ALTERNATIVE PRODUCTS:  
CC Event-Alternative splicing; Named isoforms=2;  
CC Name=Short;  
CC IsoId=P08165-1; Sequence=Displayed;  
CC Name=Long;  
CC IsoId=P08165-2; Sequence=VSP\_003415;  
CC Note=Represents 10-20% of all adrenodoxin reductase mRNAs and  
CC seems to be inactive;  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; D83475; BA011921.1; -;  
DR EMBL; D83472; BA011921.1; JOINED.  
DR EMBL; D83473; BA011921.1; JOINED.  
DR EMBL; D83474; BA011921.1; JOINED.  
DR EMBL; M17029; AAA30362.1; -;  
DR EMBL; D00211; BAA00150.1; -;  
DR EMBL; X13736; CAA32002.1; -;  
DR PIR; JTO751; JTO751.  
DR PDB; 1CJC; 12-APR-99.  
DR PDB; 1E1L; 24-SEP-00.  
DR PDB; 1E1K; 24-SEP-00.  
DR PDB; 1E1M; 24-SEP-00.  
DR PDB; 1E6E; 09-AUG-01.  
DR InterPro: IPR000759; Adnrdx\_reductase.  
DR PRINTS: PR00419; ADXRDTASE.  
KW Electron transport; Oxidoreductase; Flavoprotein; NADP; FAD;  
KW Mitochondrion; Transit peptide; Alternative splicing; 3D-structure.  
KW TRANSIT 1 32 MITOCHONDRION  
FT CHAIN 33 492 NADPH:ADRENODOXIN OXIDOREDUCTASE.  
FT VARSPPLIC 204 204 E -> EVLLICQ (in isoform long).  
FT /FtId=VSP\_003415.  
FT G -> R (IN REF. 3).  
FT FGVAFDPEVKNV I -> VWLALITPRSMIL (IN REF. 3).  
FT QDAYH -> RYRIIL (IN REF. 3).  
FT CONFLICT 124 128

FT CONFLICT 268  
FT CONFLICT 317  
FT CONFLICT 323  
FT CONFLICT 333  
FT CONFLICT 352  
FT STRAND 40  
FT STRAND 44  
FT STRAND 48  
FT STRAND 60  
FT STRAND 65  
FT STRAND 69  
FT STRAND 77  
FT STRAND 78  
FT STRAND 81  
FT STRAND 82  
FT STRAND 85  
FT STRAND 86  
FT STRAND 88  
FT STRAND 92  
FT STRAND 93  
FT STRAND 101  
FT STRAND 102  
FT STRAND 104  
FT STRAND 105  
FT STRAND 110  
FT STRAND 114  
FT STRAND 115  
FT STRAND 117  
FT STRAND 118  
FT STRAND 120  
FT STRAND 126  
FT STRAND 129  
FT STRAND 132  
FT STRAND 138  
FT STRAND 145  
FT STRAND 148  
FT STRAND 150  
FT STRAND 151  
FT STRAND 152  
FT STRAND 154  
FT STRAND 162  
FT STRAND 163  
FT STRAND 164  
FT STRAND 166  
FT STRAND 169  
FT STRAND 170  
FT STRAND 176  
FT STRAND 183  
FT STRAND 187  
FT STRAND 197  
FT STRAND 200  
FT STRAND 203  
FT STRAND 204  
FT STRAND 205  
FT STRAND 210  
FT STRAND 217  
FT STRAND 218  
FT STRAND 223  
FT STRAND 227  
FT STRAND 232  
FT STRAND 234  
FT STRAND 246  
FT STRAND 247  
FT STRAND 249  
FT STRAND 250  
FT STRAND 254  
FT STRAND 257  
FT STRAND 260  
FT STRAND 262  
FT STRAND 266  
FT STRAND 269  
FT STRAND 272  
FT STRAND 286  
FT STRAND 291  
FT STRAND 298  
FT STRAND 299  
FT STRAND 302  
FT STRAND 307  
FT STRAND 310  
FT STRAND 317  
FT STRAND 320  
FT STRAND 324  
FT STRAND 335  
FT STRAND 338  
FT STRAND 340  
FT STRAND 342  
FT STRAND 353  
FT STRAND 359  
FT STRAND 364  
FT STRAND 371  
FT STRAND 375  
FT STRAND 379  
FT STRAND 380  
FT STRAND 383  
FT STRAND 384  
FT STRAND 385  
FT STRAND 386  
FT STRAND 387  
FT STRAND 388  
FT STRAND 389  
FT STRAND 390  
FT STRAND 392  
FT STRAND 393  
FT STRAND 394  
FT STRAND 396  
FT STRAND 398  
FT STRAND 399  
FT STRAND 402  
FT STRAND 404  
FT STRAND 405  
FT STRAND 428

Query Match 50.5%; Score 50; DB 1; Length 492;

K -> R (IN REF. 3).  
PS -> RL (IN REF. 3).  
RAGRIAYTR -> ARRSAMOSPE (IN REF. 3).  
TRAVPTGVEDL -> HPSAHWCGGP (IN REF. 3).

Best Local Similarity 66.7%; Pred. No. 14;  
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3 PPKMPPMPW 11  
1 1 1 1 1  
Db 3 PPKMPPMPW 11

## RESULT 7

ATP8\_PELSU STANDARD; PRT; 55 AA.  
AC 079674;  
DT 15-JUL-1999 (Rel. 38, Last sequence update)  
DT 15-JUL-1999 (Rel. 38, Last sequence update)  
DE 28-FEB-2003 (Rel. 41, Last annotation update)  
GN ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6U).  
OS Pelomedusa subrufa (African side-necked turtle).  
OC Mitochondrion.  
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Testudines; Pleurodira; Pelomedusidae; Pelomedusa.  
OX NCBI\_TaxID=44522;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Zaroya R.;

RL Submitted (DEC-1997) to the EMBL/Genbank/DBJ databases.  
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT  
(CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPase COMPLEX.  
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +  
H(+)(out).  
CC -1- SUBCELLULAR LOCATION: Membrane-bound.  
CC -1- SIMILARITY: BELONGS TO THE ATPase PROTEIN 8 FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC EMBL: AF039066; AAD05054.1; -  
DR PIR: T11105; T11105.  
DR InterPro: IPR001421; ATPase8\_mit.  
DR Pfam: PF00895; ATP-synl\_8; 1.  
KW Hydrogen ion transport, CF(0); Mitochondrion; Transmembrane.  
FT TRANSMEM 4 24  
SQ SEQUENCE 55 AA: 6536 MW; D8D4BC8F8651A001 CRC64;

Query Match 48.5%; Score 48; DB 1; Length 55;  
Best Local Similarity 71.4%; Pred. No. 3.5;  
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LPMKMPW 8  
1 1 1 1 1  
Db 48 MPMKMPW 54

## RESULT 8

ELO1\_HUMAN STANDARD; PRT; 279 AA.  
AC Q9BW60; Q9NVD9; Q9Y396;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DE 15-SEP-2003 (Rel. 42, Last annotation update)  
DE Elongation of very long chain fatty acids protein 1 (CGI-88).  
GN ELOVL1 OR SSC1.  
OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.

RX MEDLINE=20272150; PubMed=10810093;  
RA Lai C.-H., Chou C.-Y., Chang L.-Y., Liu C.-S., Lin W.-C.;  
RT "Identification of novel human genes evolutionarily conserved in  
RL Caenorhabditis elegans by comparative proteomics.";  
RN Genome Res. 10:703-713(2000).  
RN [2]

RP SEQUENCE FROM N.A.  
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,  
RA Nishikawa T., Nagai K., Sugano S., Aotsuka S., Yoshikawa Y.,  
RA Matsunawa H., Ishii S., Kawai Y., Saito K., Yamamoto J., Wakamatsu A.,  
RA Nakamura Y., Nagahari K., Masuko Y., Sasaki N.,  
RT "NEO human cDNA sequencing project.";  
RN Submitted (FEB-2000) to the EMBL/Genbank/DBJ databases.  
RN [3]

RP SEQUENCE FROM N.A.  
RC TISSUE=Kidney;  
RX MEDLINE=22388257; PubMed=12477932;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Scheffer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Wax S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loggellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
RA Bosak S.A., McKernan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Huiyk S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butlerfield J.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,  
RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length  
RL human and mouse cDNA sequences.";  
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

CC -1- FUNCTION: Could be implicated in tissue-specific synthesis of very  
CC long chain fatty acids and sphingolipids. May catalyze one or both  
CC of the reduction reaction in fatty acid elongation, i.e.,  
CC conversion of beta-ketoacyl CoA to beta-hydroxyacyl CoA or  
CC reduction of trans-2-enoyl CoA to the saturated acyl CoA  
CC derivative (By similarity).  
CC -1- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic  
CC reticulum (Potential).  
CC -1- SIMILARITY: BELONGS TO THE ELO FAMILY.  
CC -1- CAUTION: Ref.1 sequence differs from that shown due to a  
CC frameshift in position 189.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC EMBL: AF151846; AAD34083.1; ALT\_FRAME.  
DR EMBL: AK001653; BAA91813.1; -  
DR EMBL: BC000618; AAH00618.1; -  
DR Genew: HGNC:14418; ELOVL1.  
DR InterPro: IPR002076; GNS1\_SUR4.  
DR Pfam: PF01151; ELO\_1.

DR PROSITE: PS01188; ELO\_1.  
KW Fatty acid biosynthesis; Transmembrane; Endoplasmic reticulum.  
FT TRANSMEM 23 43  
FT TRANSMEM 61 81  
FT TRANSMEM 176 196  
FT TRANSMEM 201 221  
FT TRANSMEM 231 251  
FT TRANSMEM 275 277  
FT SITE  
FT CONFLICT 68 68  
FT S -> P (IN REF. 2).

SQ SEQUENCE 279 AA: 32663 MW: B168EE4C7EAF92A6 CRC64;  
 Query Match 48.0%; Score 47.5; DB 1; Length 279;  
 Best Local Similarity 66.7%; Pred. No. 17;  
 Matches 6; Conservative 1; Mismatches 1; Indels 1; Gaps 1;

QY 1 ILPMKMPMW 9  
 Db 147 VLPMSW-WW 154

RESULT 9  
 ELO1 MOUSE  
 ID 09JUT5.09D1B2. STANDARD: PRT: 279 AA.  
 AC 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 15-SEP-2003 (Rel. 42, Last annotation update)  
 DE Elongation of very long chain fatty acids protein 1.  
 GN ELOVL1 OR SSCI.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-BALB/C; TISSUE=Liver;  
 RX MEDLINE=20253178; PubMed=10791983;  
 RA Twisk P., Westerberg R., Silve S., Asadi A., Jakobsson A., Cannon B.,  
 RA Tolson G., Jacobsson A.;  
 RT "Role of a new mammalian gene family in the biosynthesis of very long  
 RT chain fatty acids and sphingolipids";  
 RL J. Cell Biol. 149:707-718(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Breast tumor;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strusberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., BueLOW K.H., Scheefel C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carinci P., Prange C.,  
 RA Bosa S.S., Loguella N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Rask S.A., McKernan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,  
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RT human and mouse cDNA sequences";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [3]  
 RP SEQUENCE OF 78-279 FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Embryo;  
 RX MEDLINE=21085660; PubMed=11217851;  
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
 RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaoka I.,  
 RA Saito T., Okazaki Y., Gojibori T., Bono H., Kasukawa T., Saito R.,  
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
 RA Fleischmann W., Gaasterland T., Gliss C., King B., Kochia H.,  
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
 RA Schiml L.M., Stabili F., Suzuki R., Tomita M., Wagner L., Washio T.,  
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
 RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,  
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
 RA Gustinich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,

RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
 RA Sasaki H., Sato K., Schoenbach C., Sey T., Shibata Y., Storch K.-F.,  
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilming L.,  
 RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohsaki S.,  
 RA Hayashizaki Y.;  
 RT "Functional annotation of a full-length mouse cDNA collection";  
 RL Nature 409:685-690(2001).  
 CC -I- FUNCTION: Could be implicated in tissue-specific synthesis of very  
 CC long chain fatty acids and sphingolipids. May catalyze one or both  
 CC of the reduction reaction in fatty acid elongation, i.e.,  
 CC conversion of beta-ketoacyl CoA to beta-hydroxyacyl CoA or  
 CC reduction of trans-2-enoyl CoA to the saturated acyl CoA  
 CC derivative.  
 CC -I- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic  
 CC reticulum (potential).  
 CC -I- TISSUE SPECIFICITY: Expressed in a broad variety of tissues.  
 CC Highly expressed in stomach, lung, kidney, skin and intestine.  
 CC Moderately expressed in white adipose tissue, liver, spleen,  
 CC brain, brown adipose tissue, heart and muscle. Weakly expressed in  
 CC testis.  
 CC -I- SIMILARITY: BELONGS TO THE ELO FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL; AF170907; AAF72572.1; -;  
 CC EMBL; BC006735; AAH06735.1; -;  
 CC EMBL; AK003743; BAB22975.1; -;  
 CC MGD; MGI:1858959; Elov11.SUR4.  
 CC InterPro; IPR002076; GMS1\_SUR4.  
 CC Pfam; PF01151; ELO; 1.  
 CC PROSITE; PS01188; ELO; 1.  
 CC Fatty acid biosynthesis; Transmembrane; Endoplasmic reticulum.  
 CC TRANSMEM 23 43  
 CC TRANSMEM 61 81 POTENTIAL.  
 CC TRANSMEM 176 196 POTENTIAL.  
 CC TRANSMEM 203 223 POTENTIAL.  
 CC TRANSMEM 231 251 POTENTIAL.  
 CC SITE 275 277 ENDOPLASMIC RETICULUM RETRIEVAL MOTIF  
 CC (POTENTIAL).  
 CC YE -> MR (IN REF. 3).  
 FT CONFLICT 78 79  
 FT SEQUENCE 279 AA: 32678 MW: CA5A1CF5FD82F76 CRC64;  
 SQ  
 Query Match 48.0%; Score 47.5; DB 1; Length 279;  
 Best Local Similarity 66.7%; Pred. No. 17;  
 Matches 6; Conservative 1; Mismatches 1; Indels 1; Gaps 1;

QY 1 ILPMKMPMW 9  
 Db 147 VLPMSW-WW 154

RESULT 10  
 ATP8\_GADMO  
 ID ATP8\_GADMO STANDARD: PRT: 55 AA.  
 AC P15996.  
 DT 01-APR-1990 (Rel. 14, Created)  
 DT 01-APR-1990 (Rel. 14, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).  
 DE MTPAT8 OR ATP8  
 GN MTPAT8 OR ATP8  
 OS Gadus morhua (Atlantic cod).  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Paracanthopterygii; Gadiformes; Gadidae; Gadus.  
 OX NCBI\_TaxID=8049;



```

RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-Norwegian coastal 1; TISSUE=Liver;
RX MEDLINE=90174958; PubMed=2308841;
RT Johansen S., Gaddal P.H., Johansen T.;
RT "Organization of the mitochondrial genome of Atlantic cod, Gadus morhua.";
RL Nucleic Acids Res. 18:411-419(1990).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN-Norwegian coastal 1;
RX MEDLINE=96414925; PubMed=8817926;
RT Johansen S., Bakke I.;
RT "The complete mitochondrial DNA sequence of Atlantic cod (Gadus morhua): relevance to taxonomic studies among codfishes.";
RL Mol. Mar. Biol. Biotechnol. 5:203-214(1996).
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (In) -> ADP + phosphate + H(+) (Out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC -----
DR EMBL: X17659; CAA35655.1; -
DR EMBL: X99772; CAA68110.1; -
DR PIR: S08424; S08424.
DR InterPro: IPR001421; ATPase8_mit.
DR Pfam: PF00895; ATP-synt_8; 1.
DR Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
KW TRANSMEM 4 POTENTIAL.
FT SEQUENCE 55 AA; 6481 MW; E85C81E63DB48B15 CRC64;
SQ
Query Match 47.5%; Score 47; DB 1; Length 55;
Best Local Similarity 83.3%; Pred. No. 4.7;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 PKMKPW 8
DB 49 PMNMPW 54

```

```

RN [2]
RP SEQUENCE FROM N.A.
RC SPECIES=S. salar; TISSUE=Liver;
RX MEDLINE=20018174; PubMed=10548724;
RT Hurst C.D., Bartlett S.E., Davidson W.S., Bruce I.J.;
RT "The complete mitochondrial DNA sequence of the Atlantic salmon, Salmo salar.";
RL Gene 239:237-242(1999).
RN [3]
RP SEQUENCE FROM N.A.
RC SPECIES=S. salar;
RA Arnason U., Johnsen E., Rasmussen A.S.;
RT "The complete mitochondrial genome sequence of a teleost, Salmo salar, and comparisons with other salmoniformes.";
RT Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (In) -> ADP + phosphate + H(+) (Out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC -----
DR EMBL: L29771; AAB03351.1; -
DR EMBL: U12143; AAD04737.1; -
DR PIR: AF133701; AAF61382.1; -
DR PIR: T09861; T09861.
DR PIR: T09951; T09951.
DR InterPro: IPR001421; ATPase8_mit.
DR Pfam: PF00895; ATP-synt_8; 1.
DR Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
KW TRANSMEM 4 POTENTIAL.
FT SEQUENCE 55 AA; 6413 MW; D02920C3E346925F CRC64;
SQ
Query Match 47.5%; Score 47; DB 1; Length 55;
Best Local Similarity 83.3%; Pred. No. 4.7;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3 PKMKPW 8
DB 49 PMNMPW 54

```

```

CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +
CC H(+)(out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: LA2813; AAC38025.1; -.
CC PIR: S68132; S68132.
CC InterPro: IPR001421; ATPase8_mit.
CC Pfam: PF00895; ATP-synt_8; 1.
CC Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
CC KW SEQUENCE 55 AA; 6523 MW; 95343043B5B2DC53 CRC64;
SQ
Query Match 47.5%; Score 47; DB 1; Length 55;
Best Local Similarity 83.3%; Pred. No. 4.7;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 PMKMPW 8
ID 1 1 1 1
Db 49 PMNMPW 54

RESULT 13
ATP8_SALAL STANDARD; PRT; 55 AA.
AC O9XN27;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
GN MTAtp8 OR ATP8 OR ATPASE8.
OS Salvelinus alpinus (Arctic char).
OS Mitochondrion.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Proctacanthopterygii; Salmoniformes; Salmonidae; Salvelinus.
OC NCBI_TaxID=8036;
RN [1]
RP SEQUENCE FROM N.A.
RA Dolron S., Blier P.U., Bernatchez L.;
RT "A comparative analysis of complete sequence of mitochondrial genome
RT between brook char (Salvelinus fontinalis) and arctic char (S.
RT alpinus)".
RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +
CC H(+)(out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: AF154851; AAD41389.1; -.
CC InterPro: IPR001421; ATPase8_mit.
CC Pfam: PF00895; ATP-synt_8; 1.
CC Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
CC KW SEQUENCE 55 AA; 6455 MW; 71EA30C2E346924A CRC64;
SQ

```

```

Query Match 47.5%; Score 47; DB 1; Length 55;
Best Local Similarity 83.3%; Pred. No. 4.7;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 PMKMPW 8
ID 1 1 1 1
Db 49 PMNMPW 54

RESULT 14
ATP8_SALFO STANDARD; PRT; 55 AA.
AC O9XN35;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
GN MTAtp8 OR ATP8 OR ATPASE8.
OS Salvelinus fontinalis (Brook trout) (Brook char).
OS Mitochondrion.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Proctacanthopterygii; Salmoniformes; Salmonidae; Salvelinus.
OC NCBI_TaxID=8038;
RN [1]
RP SEQUENCE FROM N.A.
RA Dolron S., Blier P.U., Bernatchez L.;
RT "A comparative analysis of complete sequence of mitochondrial genome
RT between brook char (Salvelinus fontinalis) and arctic char (S.
RT alpinus)".
RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT
CC (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.
CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+)(in) = ADP + phosphate +
CC H(+)(out).
CC -1- SUBCELLULAR LOCATION: Membrane-bound.
CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: AF154850; AAD41376.1; -.
CC InterPro: IPR001421; ATPase8_mit.
CC Pfam: PF00895; ATP-synt_8; 1.
CC Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.
CC KW SEQUENCE 55 AA; 6443 MW; D02930C2E346925F CRC64;
SQ
Query Match 47.5%; Score 47; DB 1; Length 55;
Best Local Similarity 83.3%; Pred. No. 4.7;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 PMKMPW 8
ID 1 1 1 1
Db 49 PMNMPW 54

RESULT 15
ATP8_SCYCA STANDARD; PRT; 55 AA.
AC O79405;
DT 15-DEC-1998 (Rel. 37, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE ATP synthase protein 8 (EC 3.6.3.14) (ATPase subunit 8) (A6L).
GN MTAtp8 OR ATP8 OR ATPASE8.
OS Scyllorhinus canicula (Spotted dogfish) (Spotted catshark).
OS Mitochondrion.
SQ

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;  
 OC Elasmobranchii; Galeomorphii; Galeoidea; Carcharhiniformes;  
 OC Scyliorhinidae; Scyliorhinus.  
 OX NCBI\_TaxID=7830;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Muscle;  
 RX MEDLINE=98393590; PubMed=9725850;  
 RA Delarbre C., Spruyt N., Delmarre C., Gallut C., Barriel V.,  
 RA Janvier P., Laudet V., Gachelin G.;  
 RT "The complete nucleotide sequence of the mitochondrial DNA of the  
 dogfish, Scyliorhinus canicula.";  
 RL Genetics 150:331-344(1998).  
 CC -1- FUNCTION: THIS IS ONE OF THE CHAINS OF THE NONENZYMATIC COMPONENT  
 (CF(0) SUBUNIT) OF THE MITOCHONDRIAL ATPASE COMPLEX.  
 CC -1- CATALYTIC ACTIVITY: ATP + H(2)O + H(+) (in) = ADP + phosphate +  
 H(+) (out).  
 CC -1- SUBCELLULAR LOCATION: Membrane-bound.  
 CC -1- SIMILARITY: BELONGS TO THE ATPASE PROTEIN 8 FAMILY.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL: Y16067; CAA76023.1; -.  
 DR PIR: T11304; T11304.  
 DR InterPro: IPR001421; ATPase8\_mlt.  
 DR Pfam: PF00895; ATP-synt\_8; 1.  
 KM Hydrogen ion transport; CF(0); Mitochondrion; Transmembrane.  
 FT TRANSMEM 4 24 POTENTIAL.  
 SQ SEQUENCE 55 AA; 6607 MW; 075956C2A3DF05B9 CRC64;

Query Match 47.5%; Score 47; DB 1; Length 55;  
 Best local Similarity 83.3%; Pred. No. 4.7;  
 Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 PKKMPW 8  
 |||||  
 Db 49 PMNMPW 54

Search completed: October 2, 2003, 10:02:01  
 Job time : 25 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 09:59:17 : Search time 105 Seconds  
(without alignments)  
31.949 Million cell updates/sec

Title: US-09-444-281-85  
Perfect score: 99  
Sequence: 1 ILPMKPMWPMWR 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

SPTREMBL\_23:\*  
1: sp\_archaea:\*  
2: sp\_bacteria:\*  
3: sp\_fungi:\*  
4: sp\_human:\*  
5: sp\_invertebrate:\*  
6: sp\_mammal:\*  
7: sp\_mhc:\*  
8: sp\_organelle:\*  
9: sp\_phage:\*  
10: sp\_plant:\*  
11: sp\_rodent:\*  
12: sp\_virus:\*  
13: sp\_vertebrate:\*  
14: sp\_unclassified:\*  
15: sp\_rvirts:\*  
16: sp\_bacteriap:\*  
17: sp\_archaeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	59.6	780	16	08PE93	08PE93 xanthomonas
2	57.6	723	12	09DUC4	09DUC4 tt virus. o
3	55.6	49	12	09DTR0	09DTR0 tt virus. o
4	55.6	152	2	08RPF4	08RPF4 desulfitoba
5	55.6	208	16	08PBI7	08PBI7 xanthomonas
6	55.6	342	4	096BE4	096BE4 homo sapien
7	55.6	748	12	09DTR1	09DTR1 tt virus. o
8	55.6	750	12	09DTR1	09DTR1 tt virus. o
9	54.5	1173	12	09DTR1	09DTR1 human coron
10	54.5	1173	12	09DTR1	09DTR1 human coron
11	54.5	1173	12	09DTR1	09DTR1 human coron
12	54.5	1173	12	09DTR1	09DTR1 human coron
13	54.5	1383	12	084712	084712 porcine epi
14	54.5	1383	12	084712	084712 porcine epi
15	54.5	1383	12	084712	084712 porcine epi
16	54.5	1386	12	08Q98	08Q98 porcine epi

17	53.5	54.0	299	4	09Y4N1	09Y4N1 homo sapien
18	53	53.5	216	5	09W476	09W476 drosophila
19	53	53.5	257	17	08TWM9	08TWM9 methanopyru
20	53	53.5	328	12	08B9M6	08B9M6 rachiplusia
21	53	53.5	331	12	092380	092380 bombyx mori
22	53	53.5	600	5	081GB8	081GB8 drosophila
23	53	53.5	1245	3	09Y7V5	09Y7V5 trichoderma
24	52.5	53.0	640	2	0934J3	0934J3 prevotella
25	52	52.5	102	16	08P4Z9	08P4Z9 xanthomonas
26	52	52.5	105	16	08P4Z9	08P4Z9 xanthomonas
27	52	52.5	351	16	08DUN5	08DUN5 xanthomonas
28	51	51.5	55	8	09B6T0	09B6T0 eudromia el
29	51	51.5	298	17	08ZU59	08ZU59 pyrobaculum
30	51	51.5	530	4	013161	013161 homo sapien
31	51	51.5	689	16	08Y85	08Y85 anabena sp
32	50.5	51.0	214	5	09N9T4	09N9T4 leishmania
33	50.5	51.0	970	12	09Y1W9	09Y1W9 melanoplus
34	50.5	51.0	988	12	091HP7	091HP7 oedeleus as
35	50	50.5	55	8	08SEB4	08SEB4 elenia fal
36	50	50.5	83	16	09WYF1	09WYF1 thermotoga
37	50	50.5	327	16	09AUN3	09AUN3 oryza sativ
38	50	50.5	337	16	092Y02	092Y02 rhizobium m
39	50	50.5	466	4	075035	075035 homo sapien
40	50	50.5	746	12	09JH31	09JH31 tt virus. o
41	49.5	50.0	157	5	09Y0E8	09Y0E8 drosophila
42	49.5	50.0	198	10	08GZX7	08GZX7 oryza sativ
43	49.5	50.0	296	2	068125	068125 rhodospirillum rubrum
44	49.5	50.0	310	11	08CB00	08CB00 mus musculus
45	49.5	50.0	806	10	09FGM0	09FGM0 arabidopsis

## ALIGNMENTS

RESULT 1  
08PE93 PRELIMINARY; PRT; 780 AA.  
AC 08PE93: MEDLINE-22022145; PubMed-12024217;  
DT 01-OCT-2002 (TREMREL. 22, Last sequence update)  
DT 01-OCT-2002 (TREMREL. 22, Last annotation update)  
DE Hypothetical protein XCC0088.  
OS Xanthomonas campestris (pv. campestris).  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Xanthomonadales;  
OC Xanthomonadaceae; Xanthomonas.  
OX NCBI\_TaxID=340;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=ATCC 33913 / NCPPB 528;  
RX MEDLINE-22022145; PubMed-12024217;  
RA da Silva A.C.R., Ferro J.A., Reinach F.C., Farah C.S., Furian L.R.,  
RA Quaggio R.B., Monteiro-Vitorello C.B., Van Sluys M.A., Almeida N.F.,  
RA Alves L.M.C., do Amaral A.M., Bertolini M.C., Camargo L.E.A.,  
RA Camarotte G., Camarotte F., Cardozo J., Chamberg F., Ciapina L.P.,  
RA Ciccarelli R.M.B., Coutinho L.L., Cursino-Santos J.R., El-Dorri H.,  
RA Faria J.B., Ferreira A.J.S., Ferreira R.C.C., Ferro M.I.T.,  
RA Fornighieri E.F., Franco M.C., Greggio C.C., Gruber A.,  
RA Katsuyama A.M., Kishi L.T., Leite R.P., Lemos E.G.M., Lemos M.V.F.,  
RA Locali E.C., Machado M.A., Madeira A.M.B.N., Martinez-Rossi N.M.,  
RA Martins E.C., Meidants J., Menck C.F.M., Miyaki C.Y., Moon D.H.,  
RA Moreira L.M., Novo M.T.M., Okura V.K., Oliveira M.C., Oliveira V.R.,  
RA Pereira H.A., Rossi A., Sena J.A.D., Silva C., de Souza R.F.,  
RA Spinoia L.A.F., Takita M.A., Tamura R.E., Teixeira E.C., Tezza R.I.D.,  
RA Trindade dos Santos M., Truffi D., Tsai S.M., White F.F.,  
RA Setubal J.C., Kitajima J.P.;  
RT "Comparison of the genomes of two Xanthomonas pathogens with differing  
RT host specificities";  
RL Nature 417:459-463(2002).  
DR EMBL: AE012102; AAC39407.1; -  
KW Hypothetical protein; Complete proteome.  
SQ SEQUENCE 780 AA; 85074 MW; 12867434D1852549 CRC64;

Query Match 59.6%; Score 59; DB 16; Length 780;  
 Best Local Similarity 75.0%; Pred. No. 13;  
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 4 WKPMW 11  
 111111  
 148 WPMWPMW 155

## RESULT 2

09DUC4 PRELIMINARY; PRT; 723 AA.  
 ID 09DUC4;  
 AC 09DUC4;  
 DT 01-MAR-2001 (TREMBLrel. 16, Created)  
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)  
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)  
 DE ORF1.  
 OS TT virus.  
 OS Viruses; ssDNA viruses; unclassified ssDNA viruses.  
 OX NCBI\_TaxID=68887;  
 RN [1]  
 RC SEQUENCE FROM N.A.  
 RC STRAIN=MF-TTV9;  
 RA Okamoto H.;  
 RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RC SEQUENCE FROM N.A.  
 RC STRAIN=MF-TTV9;  
 RA MEDLINE=20534983; PubMed=11080484;  
 RA Okamoto H., Nishizawa T., Tawara A., Peng Y., Takahashi M.,  
 RA Kishimoto J., Tanaka T., Miyakawa Y., Mayumi M.;  
 RT "Species-specific TT viruses in humans and nonhuman primates and their  
 RT phylogenetic relatedness";  
 RT Virology 277:368-378(2000).  
 DR EMBL: AB041959; BAB19313.1;  
 DR InterPro: IPR001563; Serine\_carboxypept.  
 DR InterPro: IPR004219; Tyrosine\_Unk.  
 DR Pfam: PF02856; TT\_ORF1; 1  
 DR PROSITE: PS00131; CARBOXYPEPT\_SER\_SER; 1  
 DR SEQUENCE 723 AA; 85393 MW; 232D003096766344 CRC64;  
 SO

Query Match 57.6%; Score 57; DB 12; Length 73;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 7 PMWPMR 13  
 1111111  
 2 PMWPMR 8

## RESULT 3

09DTR80 PRELIMINARY; PRT; 49 AA.  
 ID 09DTR80;  
 AC 09DTR80;  
 DT 01-MAR-2001 (TREMBLrel. 16, Created)  
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)  
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)  
 DE ORF1 (Fragment).  
 OS TT virus.  
 OS Viruses; ssDNA viruses; unclassified ssDNA viruses.  
 OX NCBI\_TaxID=68887;  
 RN [1]  
 RC SEQUENCE FROM N.A.  
 RC STRAIN=TYM9;  
 RA MEDLINE=20568739; PubMed=11118348;  
 RA Okamoto H., Nishizawa T., Tawara A., Takahashi M., Kishimoto J.,  
 RA Sai T., Sugai Y.;  
 RT "TT virus mRNAs detected in the bone marrow cells from an infected  
 RT individual";  
 RT Biochem. Biophys. Res. Commun. 279:700-707(2000).  
 DR EMBL: AB050449; BAB19930.1;  
 FT NON\_TER 49  
 SO SEQUENCE 49 AA; 7225 MW; 1DA6F8F1AB69AA43 CRC64;

Query Match 55.6%; Score 55; DB 12; Length 49;  
 Best Local Similarity 44.4%; Pred. No. 3; 6;  
 Matches 8; Conservative 1; Mismatches 3; Indels 6; Gaps 1;

OY 2 LPKMPW-----WPMR 13  
 : | | | |  
 1 MAWTWWRORRRRRWPMR 18

## RESULT 4

08RPF4 PRELIMINARY; PRT; 152 AA.  
 ID 08RPF4;  
 AC 08RPF4;  
 DT 01-JUN-2002 (TREMBLrel. 21, Created)  
 DT 01-JUN-2002 (TREMBLrel. 21, Last sequence update)  
 DT 01-MAR-2003 (TREMBLrel. 23, Last annotation update)  
 DE Hypothetical 16.9 kDa protein.  
 OS Desulfotobacterium hafnense.  
 OS Bacteria; Firmicutes; Clostridia; Clostridiales; Peptococcaceae;  
 OC Desulfotobacterium.  
 OX NCBI\_TaxID=49338;  
 RN [1]  
 RC SEQUENCE FROM N.A.  
 RC STRAIN=DCB-2;  
 RA Davis J.K., Tiedje J.M.;  
 RT "Sequence and transcriptional analysis of reductive dehalogenase genes  
 RT of Desulfotobacterium";  
 RT Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.  
 DR EMBL: AF403185; AAL87800.1;  
 DR InterPro: IPR006311; Tat.  
 DR TIGRfams: TIGR01409; Tat\_signal\_seq; 1.  
 KW Hypothetical protein.  
 SO SEQUENCE 152 AA; 16876 MW; 2F5A00F01E70A379 CRC64;

Query Match 55.6%; Score 55; DB 2; Length 152;  
 Best Local Similarity 85.7%; Pred. No. 9; 7;  
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 PMKPMW 9  
 111111  
 146 PMKPMW 152

## RESULT 5

08PB17 PRELIMINARY; PRT; 208 AA.  
 ID 08PB17;  
 AC 08PB17;  
 DT 01-OCT-2002 (TREMBLrel. 22, Created)  
 DT 01-OCT-2002 (TREMBLrel. 22, Last sequence update)  
 DT 01-OCT-2002 (TREMBLrel. 22, Last annotation update)  
 DE Hypothetical protein XCC1132.  
 GN XCC1132.  
 OS Xanthomonas campestris (pv. campestris).  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Xanthomonadales;  
 OC Xanthomonadaceae; Xanthomonas.  
 OX NCBI\_TaxID=340;  
 RN [1]  
 RC SEQUENCE FROM N.A.  
 RC STRAIN=ATCC 33913 / NCPPB 528;  
 RX MEDLINE=22022145; PubMed=12024217;  
 RA da Silva A.C.R., Ferro J.A., Reinach F.C., Farah C.S., Furlan L.R.,  
 RA Quaggio R.B., Monteiro-Vitorello C.B., Van Sluys M.A., Almeida N.F.,  
 RA Alves L.M.C., do Amaral A.M., Bertolini M.C., Camargo L.E.A.,  
 RA Camarotte G., Canhaman F., Cardoso J., Chamberggo F., Clapina L.P.,  
 RA Ciccarelli R.M.B., Coutinho L.L., Cursino-Santos J.R., El-Dorri H.,  
 RA Faria J.B., Ferreira A.J.S., Ferreira R.C.C., Ferro M.I.T.,  
 RA Fornighieri E.F., Franco M.C., Greggio C.C., Gruber A.,  
 RA Katsuyama A.M., Kishi I.T., Leite R.P., Lemos E.G.M., Lemos M.V.F.,  
 RA Locati E.C., Machado M.A., Madeira A.M.B.N., Martinez-Rossi N.M.,  
 RA Martins E.C., Meidanis J., Menck C.F.M., Miyaki C.Y., Moon D.H.,  
 RA Moreira L.M., Novo M.T.M., Okura V.K., Oliveira M.C., Oliveira V.R.,  
 RA Pereira H.A., Rossi A., Sena J.A.D., Silva C., de Souza R.F.,

RA Spinoia L.A.F., Takita M.A., Tamura R.E., Teixeira E.C., Tezza R.I.D.,  
 RA Trindade dos Santos M., Truffi D., Tsai S.M., White F.F.,  
 RA Setubal J.C., Kitajima J.P.;  
 RT "Comparison of the genomes of two Xanthomonas pathogens with differing  
 RT host specificities."  
 RL Nature 417:459-463(2002).  
 DR EMBL: AE012212; AAM40431.1; -  
 DR InterPro: IPR003709; Vany; 1  
 DR Pfam: PF02557; Vany; 1  
 KW Hypothetical protein, complete proteome.  
 SQ SEQUENCE 208 AA; 22940 MW; 10B180F6EAF7B014 CRC64;

Query Match 55.6%; Score 55; DB 16; Length 208;  
 Best Local Similarity 75.0%; Pred. No. 13;  
 Matches 6; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 3 LPWKMPWP 10  
 DB 200 PWHMRWMP 207

RESULT 6  
 O96BE4 PRELIMINARY; PRT; 342 AA.  
 AC O96BE4;  
 DT 01-DEC-2001 (TREMBlrel. 19, Created)  
 DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)  
 DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
 DE Hypothetical protein.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Skin, and amelanotic;  
 RA Strausberg R.;  
 RL Submitted (OCT-2001) to the EMBL/Genbank/DBJ databases.  
 DR EMBL: BC015687; AAL15687.1; -  
 KW Hypothetical protein.  
 SQ SEQUENCE 342 AA; 37741 MW; 3147596F8D7DF849 CRC64;

Query Match 55.6%; Score 55; DB 4; Length 342;  
 Best Local Similarity 63.6%; Pred. No. 19;  
 Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

OY 1 LPWKMPWP 11  
 DB 296 LHPGMPGMPW 306

RESULT 7  
 O9DT81 PRELIMINARY; PRT; 748 AA.  
 AC O9DT81;  
 DT 01-MAR-2001 (TREMBlrel. 16, Created)  
 DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)  
 DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
 DE ORF1.  
 OS TT virus.  
 OC Viruses; ssDNA viruses; unclassified ssDNA viruses.  
 OX NCBI\_TaxID=68887;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=TYM8;  
 RL MEDLINE=20568739; PubMed=1118348;  
 RA Okamoto H., Nishizawa T., Tawara A., Takahashi M., Kishimoto J.,  
 Sai T., Sugai Y.;  
 RT "TT virus mRNAs detected in the bone marrow cells from an infected  
 RT individual."  
 RL Biochem. Biophys. Res. Commun. 279:700-707(2000).  
 DR EMBL: AB050448; BAB19928.1; -  
 DR InterPro: IPR004219; TVVirus\_Unk.

DR Pfam: PF02956; TT\_ORF1; 1.  
 SQ SEQUENCE 748 AA; 88552 MW; D65C8B2CA5CE26F CRC64;

Query Match 55.6%; Score 55; DB 12; Length 748;  
 Best Local Similarity 44.4%; Pred. No. 38;  
 Matches 8; Conservative 1; Mismatches 3; Indels 6; Gaps 1;

OY 2 LPWKMPW-----WPMRR 13  
 DB 1 MAWMTWMOQRRRRWPMRR 18

RESULT 8  
 O91D04 PRELIMINARY; PRT; 750 AA.  
 AC O91D04;  
 DT 01-DEC-2001 (TREMBlrel. 19, Created)  
 DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)  
 DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
 DE ORF1.  
 OS TT virus.  
 OC Viruses; ssDNA viruses; unclassified ssDNA viruses.  
 OX NCBI\_TaxID=68887;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21488921; PubMed=11601907;  
 RA Okamoto H., Nishizawa T., Takahashi M., Asabe S., Tsuda F.,  
 RA Yoshikawa A.;  
 RT "Heterogeneous distribution of TT virus of distinct genotypes in  
 RT multiple tissues from infected humans."  
 RL Virology 288:358-368(2001).  
 DR EMBL: AB060592; BAB69900.1; -  
 DR InterPro: IPR004219; TVVirus\_Unk.  
 DR Pfam: PF02956; TT\_ORF1; 1.  
 SQ SEQUENCE 750 AA; 89223 MW; 616EC86DC3469091 CRC64;

Query Match 55.6%; Score 55; DB 12; Length 750;  
 Best Local Similarity 44.4%; Pred. No. 38;  
 Matches 8; Conservative 1; Mismatches 3; Indels 6; Gaps 1;

OY 2 LPWKMPW-----WPMRR 13  
 DB 1 MAWMTWMOQRRRRWPMRR 18

RESULT 9  
 O990M4 PRELIMINARY; PRT; 1173 AA.  
 AC O990M4;  
 DT 01-JUN-2001 (TREMBlrel. 17, Created)  
 DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)  
 DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
 DE Spike glycoprotein.  
 GN S.  
 OS Human coronavirus (strain 229E).  
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
 OC Coronaviridae; Coronavirus.  
 OX NCBI\_TaxID=11137;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=229E;  
 RA Bonavia A., Holmes K.V.;  
 RT "Viral and cellular changes in a human cell line persistently infected  
 RT with human coronavirus HCoV-229E."  
 RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.  
 DR EMBL: AF344186; AAK32188.1; -  
 DR InterPro: IPR002551; Corona\_S1.  
 DR InterPro: IPR002552; Corona\_S2.  
 DR Pfam: PF01600; Corona\_S1; 1.  
 DR Pfam: PF01601; Corona\_S2; 1.  
 SQ SEQUENCE 1173 AA; 128669 MW; ABC6E0A75EBBD8A4 CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;

Best Local Similarity 85.7%; Pred. No. 74;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11  
111111  
Db 1113 KMPWMPW 1119

## RESULT 10

ID 0990M1 PRELIMINARY; PRT: 1173 AA.  
AC 0990M1;  
DT 01-JUN-2001 (TREMBlrel. 17, Created)  
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)  
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
DE Spike glycoprotein.  
GN S.  
OS Human coronavirus (strain 229E).  
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
OC Coronaviridae; Coronavirus.  
OX NCBI\_TaxID=11137;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=229E;  
RA Bonavia A., Holmes K.V.;  
RT "Viral and cellular changes in a human cell line persistently infected with human coronavirus HCoV-229E";  
RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.  
DR EMBL: AF344188; AAK32190.1; -  
DR InterPro: IPR002551; Corona\_S1.  
DR InterPro: IPR002552; Corona\_S2.  
DR Pfam: PF01600; Corona\_S1; 1.  
DR Pfam: PF01601; Corona\_S2; 1.  
SQ SEQUENCE 1173 AA; 128760 MW; B73A165A6270152A CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;  
Best Local Similarity 85.7%; Pred. No. 74;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11  
111111  
Db 1113 KMPWMPW 1119

## RESULT 11

ID 0990M3 PRELIMINARY; PRT: 1173 AA.  
AC 0990M3;  
DT 01-JUN-2001 (TREMBlrel. 17, Created)  
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)  
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
DE Spike glycoprotein.  
GN S.  
OS Human coronavirus (strain 229E).  
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
OC Coronaviridae; Coronavirus.  
OX NCBI\_TaxID=11137;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=229E;  
RA Bonavia A., Holmes K.V.;  
RT "Viral and cellular changes in a human cell line persistently infected with human coronavirus HCoV-229E";  
RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.  
DR EMBL: AF344187; AAK32189.1; -  
DR InterPro: IPR002551; Corona\_S1.  
DR InterPro: IPR002552; Corona\_S2.  
DR Pfam: PF01600; Corona\_S1; 1.  
DR Pfam: PF01601; Corona\_S2; 1.  
SQ SEQUENCE 1173 AA; 128683 MW; 9E236816082A81A CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;  
Best Local Similarity 85.7%; Pred. No. 74;

Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11  
111111  
Db 1113 KMPWMPW 1119

## RESULT 12

ID 0990M2 PRELIMINARY; PRT: 1173 AA.  
AC 0990M2;  
DT 01-JUN-2001 (TREMBlrel. 17, Created)  
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)  
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
DE Spike glycoprotein.  
GN S.  
OS Human coronavirus (strain 229E).  
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
OC Coronaviridae; Coronavirus.  
OX NCBI\_TaxID=11137;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=229E;  
RA Bonavia A., Holmes K.V.;  
RT "Viral and cellular changes in a human cell line persistently infected with human coronavirus HCoV-229E";  
RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.  
DR EMBL: AF344188; AAK32190.1; -  
DR InterPro: IPR002551; Corona\_S1.  
DR InterPro: IPR002552; Corona\_S2.  
DR Pfam: PF01600; Corona\_S1; 1.  
DR Pfam: PF01601; Corona\_S2; 1.  
SQ SEQUENCE 1173 AA; 128653 MW; 8B658FCBBD1842DA CRC64;

Query Match 54.5%; Score 54; DB 12; Length 1173;  
Best Local Similarity 85.7%; Pred. No. 74;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 KMPWMPW 11  
111111  
Db 1113 KMPWMPW 1119

## RESULT 13

ID 084712 PRELIMINARY; PRT: 1383 AA.  
AC 084712;  
DT 01-NOV-1996 (TREMBlrel. 01, Created)  
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)  
DT 01-OCT-2002 (TREMBlrel. 22, Last annotation update)  
DE Spike protein.  
OS Porcine epidemic diarrhea virus.  
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
OC Coronaviridae; Coronavirus.  
OX NCBI\_TaxID=28295;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Brl/87;  
RX MEDLINE=94231173; PubMed=8176382;  
RA Duarte M., Laude H.;  
RT "Sequence of the spike protein of the porcine epidemic diarrhoea virus.";  
RL J. Gen. Virol. 75:1195-1200(1994).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Brl/87;  
RX MEDLINE=93389433; PubMed=8397280;  
RA Bridgen A., Duarte M., Tobler K., Laude H., Ackermann M.;  
RT "Sequence determination of the nucleocapsid protein gene of the porcine epidemic diarrhoea virus confirms that this virus is a coronavirus related to human coronavirus 229E and porcine transmissible gastroenteritis virus.";  
RT J. Gen. Virol. 74:1795-1804(1993).



RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-Brl/87;  
 RX MEDLINE-94120721: PubMed-8291230;  
 RA Duarte M., Tobler K., Bridgen A., Rasschaert D., Ackermann M.,  
 RT "Sequence analysis of the porcine epidemic diarrhoea virus genome  
 between the nucleocapsid and spike protein genes reveals a polymo."  
 RL Virology 198:466-476(1994).  
 DR EMBL: Z25483: CAA80971.1: -  
 DR InterPro: IPR002551; Corona\_S1.  
 DR InterPro: IPR002552; Corona\_S2.  
 DR Pfam: PF01600; Corona\_S1; 1.  
 DR Pfam: PF01601; Corona\_S2; 1.  
 FT CONFLICT 422 422 Y -> N (IN REF. 1)  
 SQ SEQUENCE 1383 AA: 151405 MW: 741C84D5DD3BDC4D CRC64;  
  
 Query Match 54.5%; Score 54; DB 12; Length 1383;  
 Best Local Similarity 85.7%; Pred. No. 86;  
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
 QY 5 KMPMPW 11  
 DB 1322 KMPMPW 1328  
  
 RESULT 14  
 ID 091AV1 PRELIMINARY; PRT; 1383 AA.  
 AC 091AV1;  
 DT 01-DEC-2001 (TREMBLrel. 19, Created)  
 DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)  
 DE 01-OCT-2002 (TREMBLrel. 22, Last annotation update)  
 DE Spike protein.  
 OS Porcine epidemic diarrhoea virus.  
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
 OC Coronaviridae; Coronavirus.  
 OX NCBI\_TaxID-28295;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-CV777;  
 RX MEDLINE-93389433: PubMed-8397280;  
 RA Bridgen A., Duarte M., Tobler K., Laude H., Ackermann M.;  
 RT "Sequence determination of the nucleocapsid protein gene of the  
 porcine epidemic diarrhoea virus confirms that this virus is a  
 coronavirus related to human coronavirus 229E and porcine  
 transmissible gastroenteritis virus."  
 RL J. Gen. Virol. 74:1795-1804(1993).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-CV777;  
 RX MEDLINE-94120721: PubMed-8291230;  
 RA Duarte M., Tobler K., Bridgen A., Rasschaert D., Ackermann M.,  
 RT "Sequence analysis of the porcine epidemic diarrhoea virus genome  
 between the nucleocapsid and spike protein genes reveals a polymorphic  
 ORF."  
 RL Virology 198:466-476(1994).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-CV777;  
 RX MEDLINE-96112302: PubMed-8830538;  
 RA Tobler K., Ackermann M.;  
 RT "PDV leader sequence and junction sites."  
 RL Adv. Exp. Med. Biol. 380:541-542(1995).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-CV777;  
 RX MEDLINE-98455678: PubMed-9782358;  
 RA Bridgen A., Koehrhans R., Tobler K., Carvajal A., Ackermann M.;  
 RT "Further analysis of the genome of porcine epidemic diarrhoea virus."  
 RL Adv. Exp. Med. Biol. 440:781-786(1998).  
 RN [5]

RP SEQUENCE FROM N.A.  
 RC STRAIN-CV777;  
 RA Koehrhans R., Bridgen A., Ackermann M., Tobler K.;  
 RT "The complete genome sequence of porcine epidemic diarrhoea  
 coronavirus."  
 RL Submitted (FEB-2001) to the EMBL/Genbank/DBJ databases.  
 DR EMBL: AF353511; AAK38656.1; -  
 DR InterPro: IPR002551; Corona\_S1.  
 DR InterPro: IPR002552; Corona\_S2.  
 DR Pfam: PF01600; Corona\_S1; 1.  
 DR Pfam: PF01601; Corona\_S2; 1.  
 SQ SEQUENCE 1383 AA: 151352 MW: 022E5E5E5435876D CRC64;  
  
 Query Match 54.5%; Score 54; DB 12; Length 1383;  
 Best Local Similarity 85.7%; Pred. No. 86;  
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
 QY 5 KMPMPW 11  
 DB 1322 KMPMPW 1328  
  
 RESULT 15  
 ID 08B482 PRELIMINARY; PRT; 1383 AA.  
 AC 08B482;  
 DT 01-MAR-2003 (TREMBLrel. 23, Created)  
 DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)  
 DE 01-MAR-2003 (TREMBLrel. 23, Last annotation update)  
 DE Spike protein.  
 OS Porcine epidemic diarrhoea virus.  
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Nidovirales;  
 OC Coronaviridae; Coronavirus.  
 OX NCBI\_TaxID-28295;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN-Chinju99;  
 RA Yeo S.-G., Krell P., Nagy E.;  
 RT "Cloning and nucleotide sequence analysis of spike gene of porcine  
 epidemic diarrhoea virus detected in Korea."  
 RL Submitted (OCT-2002) to the EMBL/Genbank/DBJ databases.  
 DR EMBL: AY167585; AAN86621.1; -  
 SQ SEQUENCE 1383 AA: 151582 MW: B5BA4D7DE5371A54 CRC64;  
  
 Query Match 54.5%; Score 54; DB 12; Length 1383;  
 Best Local Similarity 85.7%; Pred. No. 86;  
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
 QY 5 KMPMPW 11  
 DB 1322 KMPMPW 1328

Search completed: October 2, 2003, 10:03:57  
 Job time : 107 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 10:00:07 : Search time 25 seconds

(without alignments)  
22.002 Million cell updates/sec

Title: US-09-444-281-85

Sequence: 1 ILPMKMPMPRR 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued\_Patents\_AA:\*

1: /cgn2\_6/ptodata/1/1aa/5A.COMB.pep:\*  
2: /cgn2\_6/ptodata/1/1aa/5B.COMB.pep:\*  
3: /cgn2\_6/ptodata/1/1aa/6A.COMB.pep:\*  
4: /cgn2\_6/ptodata/1/1aa/6B.COMB.pep:\*  
5: /cgn2\_6/ptodata/1/1aa/PCITUS.COMB.pep:\*  
6: /cgn2\_6/ptodata/1/1aa/Backfile1.pep:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	99	100.0	13	US-07-715-271-1	Sequence 1, Appl
2	99	100.0	13	US-08-197-205-1	Sequence 1, Appl
3	99	100.0	13	US-08-197-205-5	Sequence 5, Appl
4	99	100.0	13	US-09-230-180-29	Sequence 29, Appl
5	99	100.0	13	US-09-230-180-30	Sequence 30, Appl
6	99	100.0	13	US-08-702-054B-16	Sequence 16, Appl
7	99	100.0	13	US-09-076-227-1	Sequence 1, Appl
8	99	100.0	13	US-09-099-631A-1	Sequence 1, Appl
9	99	100.0	13	US-09-099-631A-3	Sequence 3, Appl
10	99	100.0	13	US-09-318-195A-2	Sequence 2, Appl
11	99	100.0	13	US-09-030-619-98	Sequence 98, Appl
12	99	100.0	13	US-09-030-619-204	Sequence 204, App
13	99	100.0	13	US-09-416-481A-1	Sequence 1, Appl
14	99	100.0	13	US-09-667-486-29	Sequence 29, Appl
15	99	100.0	14	US-09-076-227-24	Sequence 24, Appl
16	99	100.0	14	US-09-076-227-36	Sequence 36, Appl
17	99	100.0	14	US-09-416-481A-24	Sequence 24, Appl
18	99	100.0	14	US-09-416-481A-36	Sequence 36, Appl
19	99	100.0	15	US-08-702-054B-7	Sequence 7, Appl
20	99	100.0	16	US-09-076-227-37	Sequence 37, Appl
21	99	100.0	17	US-09-416-481A-37	Sequence 37, Appl
22	99	100.0	17	US-09-076-227-35	Sequence 35, Appl
23	99	100.0	17	US-09-416-481A-35	Sequence 35, Appl
24	99	100.0	63	US-09-099-631A-12	Sequence 12, Appl
25	99	100.0	63	US-09-416-481A-39	Sequence 39, Appl
26	96	97.0	13	US-08-197-205-7	Sequence 7, Appl
27	96	97.0	15	US-08-702-054B-6	Sequence 6, Appl

28	95	96.0	12	4	US-09-076-227-2	Sequence 2, Appl
29	95	96.0	12	4	US-09-099-631A-5	Sequence 5, Appl
30	95	96.0	12	4	US-09-416-481A-2	Sequence 2, Appl
31	94	94.9	12	1	US-08-197-205-6	Sequence 6, Appl
32	94	94.9	12	4	US-09-076-227-25	Sequence 25, Appl
33	94	94.9	12	4	US-09-318-195A-6	Sequence 6, Appl
34	94	94.9	12	4	US-09-416-481A-25	Sequence 25, Appl
35	94	94.9	13	1	US-08-197-205-2	Sequence 2, Appl
36	94	94.9	13	4	US-09-318-195A-1	Sequence 1, Appl
37	94	94.9	13	4	US-09-318-195A-3	Sequence 3, Appl
38	94	94.9	13	4	US-09-318-195A-7	Sequence 7, Appl
39	93	93.9	13	1	US-08-197-205-3	Sequence 3, Appl
40	93	93.9	15	3	US-08-702-054B-8	Sequence 8, Appl
41	91	91.9	11	3	US-08-702-054B-9	Sequence 9, Appl
42	91	91.9	11	4	US-09-076-227-3	Sequence 3, Appl
43	91	91.9	11	4	US-09-099-631A-6	Sequence 6, Appl
44	91	91.9	11	4	US-09-416-481A-3	Sequence 3, Appl
45	91	91.9	12	1	US-08-197-205-4	Sequence 4, Appl

## ALIGNMENTS

RESULT 1  
US-07-715-271-1  
; Sequence 1, Application US/07715271  
; Patent No. 5324716  
; GENERAL INFORMATION:  
; APPLICANT: Selsted, Michael E.  
; APPLICANT: Cullor, James S.  
; TITLE OF INVENTION: BROAD SPECTRUM ANTIMICROBIAL COMPOUNDS  
; TITLE OF INVENTION: AND METHODS OF USE  
; NUMBER OF SEQUENCES: 1  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK  
; STREET: 444 So. Flower Street, Suite 2000  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: United States  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07715, 271  
; FILING DATE: 19910614  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Campbell, Cathryn  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P31 8963  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 619-535-9001  
; TELEFAX: 619-535-8949  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 13 amino acids  
; TYPE: AMINO ACID  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; US-07-715-271-1

Query Match 100.0%; Score 99; DB 1; Length 13;  
Best local Similarity 100.0%; Pred. No. 1; Le-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPRR 13  
|||||  
Db 1 ILPMKMPMPRR 13

RESULT 2  
US-08-197-205-1  
; Sequence 1, Application US/08197205  
; Patent No. 5547939  
; GENERAL INFORMATION:  
; APPLICANT: Selsted, Michael E.  
; TITLE OF INVENTION: Broad Spectrum Antimicrobial Compounds  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Campbell and Flores  
; STREET: 4370 La Jolla Village Drive, Suite 700  
; CITY: San Diego  
; STATE: California  
; COUNTRY: USA  
; ZIP: 92122  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/197,205  
; FILING DATE: 16-FEB-1994  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Campbell, Cathryn A.  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-UC 9881  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (619) 535-9001  
; TELEFAX: (619) 535-8949  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 13 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; US-08-197-205-1

Query Match 100.0%; Score 99; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 1.1e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKPMPWRR 13  
Db 1 ILPWKPMPWRR 13

RESULT 3  
US-08-197-205-5  
; Sequence 5, Application US/08197205  
; Patent No. 5547939  
; GENERAL INFORMATION:  
; APPLICANT: Selsted, Michael E.  
; TITLE OF INVENTION: Broad Spectrum Antimicrobial Compounds  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Campbell and Flores  
; STREET: 4370 La Jolla Village Drive, Suite 700  
; CITY: San Diego  
; STATE: California  
; COUNTRY: USA  
; ZIP: 92122  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/197,205  
; FILING DATE: 16-FEB-1994  
; CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:  
; NAME: Campbell, Cathryn A.  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-UC 9881  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (619) 535-9001  
; TELEFAX: (619) 535-8949  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 13 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; US-08-197-205-5

Query Match 100.0%; Score 99; DB 1; Length 13;  
Best Local Similarity 100.0%; Pred. No. 1.1e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKPMPWRR 13  
Db 1 ILPWKPMPWRR 13

RESULT 4  
US-08-915-314-29  
; Sequence 29, Application US/08915314  
; Patent No. 6180604  
; GENERAL INFORMATION:  
; APPLICANT: Fraser, Janet R.  
; APPLICANT: West, Michael H.P.  
; APPLICANT: Krieger, Timothy J.  
; APPLICANT: Taylor, Robert  
; APPLICANT: Erile, Douglas  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING  
; TITLE OF INVENTION: INFECTIONS USING ANALOGUES OF INDOLICIDIN  
; NUMBER OF SEQUENCES: 90  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: SEED AND BERRY LLP  
; STREET: 6300 Columbia Center, 701 Fifth Avenue  
; CITY: Seattle  
; STATE: Washington  
; COUNTRY: USA  
; ZIP: 98104  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/915,314  
; FILING DATE: 20-AUG-1997  
; CLASSIFICATION: 424  
; ATTORNEY/AGENT INFORMATION:  
; NAME: No. 6180604tlenburg, Ph.D., Carol  
; REGISTRATION NUMBER: 39,317  
; REFERENCE/DOCKET NUMBER: 660081.405  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (206) 622-6031  
; TELEFAX: (206) 682-6031  
; INFORMATION FOR SEQ ID NO: 29:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 13 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; US-08-915-314-29

Query Match 100.0%; Score 99; DB 3; Length 13;  
Best Local Similarity 100.0%; Pred. No. 1.1e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPWKPMPWRR 13  
Db 1 ILPWKPMPWRR 13

Db 1 ILPMKMPWMPWRR 13

## RESULT 5

US-09-230-180-30

Sequence 30, Application US/09230180

Patent No. 6183992

GENERAL INFORMATION:

APPLICANT: Kim, Sun-Chang

APPLICANT: Lee, Jae-Hyun

APPLICANT: Kang, Min-Hyung

APPLICANT: Kim, Jeong-Hyun

APPLICANT: Hong, Seung-Suh

APPLICANT: Lee, Hyun-Soo

APPLICANT: Samyang Genex Corporation

APPLICANT: Korea Advanced Institute of Science and Technology

TITLE OF INVENTION: METHOD FOR MASS PRODUCTION OF

FILE REFERENCE: 6181/0F135

CURRENT APPLICATION NUMBER: US/09/230,180

CURRENT FILING DATE: 1999-03-10

PRIOR APPLICATION NUMBER: PCT/KR98/00132

PRIOR FILING DATE: 1998-05-28

PRIOR APPLICATION NUMBER: KR 13372/1998

PRIOR FILING DATE: 1998-04-09

PRIOR APPLICATION NUMBER: KR 21312/1997

PRIOR FILING DATE: 1997-05-28

NUMBER OF SEQ ID NOS: 36

SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 30

LENGTH: 13

TYPE: PRT

ORGANISM: Bos taurus

US-09-230-180-30

## Query Match

100.0%; Score 99; DB 3; Length 13;

Best Local Similarity 100.0%; Pred. No. 1.1e-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPWMPWRR 13

Db 1 ILPMKMPWMPWRR 13

## RESULT 6

US-08-702-054B-16

Sequence 16, Application US/08702054B

Patent No. 6191254

GENERAL INFORMATION:

APPLICANT: Falls, Timothy J.

APPLICANT: Hancock, Robert E. W.

APPLICANT: Gough, Monisha

TITLE OF INVENTION: ANTIMICROBIAL CATIONIC PEPTIDES

TITLE OF INVENTION: AND METHODS OF SCREENING FOR THE SAME

NUMBER OF SEQUENCES: 44

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 4225 Executive Square, Suite 1400

CITY: La Jolla

STATE: CA

COUNTRY: USA

ZIP: 92037

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows 95

SOFTWARE: FastSeq for Windows Version 2.0b

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/702,054B

FILING DATE: 23-AUG-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,687

FILING DATE: 23-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: Haile, Lisa A.

REGISTRATION NUMBER: 38,347

REFERENCE/DOCKET NUMBER: 07420/013001

TELECOMMUNICATION INFORMATION:

TELEPHONE: 619/678-5090

TELEFAX: 619/678-5099

INFORMATION FOR SEQ ID NO: 16:

SEQUENCE CHARACTERISTICS:

LENGTH: 13 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-702-054B-16

## Query Match

100.0%; Score 99; DB 3; Length 13;

Best Local Similarity 100.0%; Pred. No. 1.1e-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPWMPWRR 13

Db 1 ILPMKMPWMPWRR 13

## RESULT 7

US-09-076-227-1

Sequence 1, Application US/09076227

Patent No. 6303575

GENERAL INFORMATION:

APPLICANT: Selsted, Michael E.

TITLE OF INVENTION: Indolicidin Analogs and Methods of Using Same

FILE REFERENCE: P-UC 3049

CURRENT APPLICATION NUMBER: US/09/076,227

CURRENT FILING DATE: 1998-05-12

NUMBER OF SEQ ID NOS: 37

SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 1

LENGTH: 13

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic

FEATURE:

NAME/KEY: MOD\_RES

LOCATION: (13)

OTHER INFORMATION: AMIDATION

US-09-076-227-1

## Query Match

100.0%; Score 99; DB 4; Length 13;

Best Local Similarity 100.0%; Pred. No. 1.1e-07;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPWMPWRR 13

Db 1 ILPMKMPWMPWRR 13

## RESULT 8

US-09-099-631A-1

Sequence 1, Application US/09099631A

Patent No. 6444645

GENERAL INFORMATION:

APPLICANT: Selsted, Michael E.

APPLICANT: Osapay, Klara

TITLE OF INVENTION: Crosslink-Stabilized Indolicidin Analogs

FILE REFERENCE: P-UC 3050

CURRENT APPLICATION NUMBER: US/09/099,631A

CURRENT FILING DATE: 1998-06-18

NUMBER OF SEQ ID NOS: 13

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 1

LENGTH: 13

```
; TYPE: PRT
; ORGANISM: Bos taurus
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (13)
; OTHER INFORMATION: AMIDATION
US-09-099-631A-1

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 9
US-09-099-631A-3
; Sequence 3, Application US/09099631A
; Patent No. 6444645
; GENERAL INFORMATION:
; APPLICANT: Seasted, Michael E.
; APPLICANT: Osapay, Klara
; TITLE OF INVENTION: Crosslink-Stabilized Indolicidin Analogs
; FILE REFERENCE: P-UC 3050
; CURRENT APPLICATION NUMBER: US/09/099,631A
; CURRENT FILING DATE: 1998-06-18
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 3
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (13)
; OTHER INFORMATION: AMIDATION
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Construct
US-09-099-631A-3

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 10
US-09-318-195A-2
; Sequence 2, Application US/09318195A
; Patent No. 6482799
; GENERAL INFORMATION:
; APPLICANT: Tuse, Daniel
; APPLICANT: Mortelmans, Kristien
; APPLICANT: Hokama, Leslie A.
; APPLICANT: Chapoy, Larry L.
; APPLICANT: Quinn, Michael H.
; APPLICANT: Large Scale Biology Corporation
; TITLE OF INVENTION: Self-Preserving Multipurpose Ophthalmic Solutions
; TITLE OF INVENTION: Incorporating a Polypeptide Antimicrobial
; FILE REFERENCE: 017942-001400S
; CURRENT APPLICATION NUMBER: US/09/318,195A
; CURRENT FILING DATE: 1999-05-25
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 2
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Indolicidin
; OTHER INFORMATION: analog Indol-12-R13-R-0H
US-09-318-195A-2

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 11
US-09-030-619-98
; Sequence 98, Application US/09030619B
; Patent No. 6503881
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 98
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cationic Peptide Analogue
US-09-030-619-98

Query Match
Best Local Similarity 100.0%; Score 99; DB 4; Length 13;
Pred. No. 1.1e-07;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13
Db 1 ILPMKMPMPWRR 13

RESULT 12
US-09-030-619-204
; Sequence 204, Application US/09030619B
; Patent No. 6503881
; GENERAL INFORMATION:
; APPLICANT: Krieger, Timothy J.
; APPLICANT: Taylor, Robert
; APPLICANT: Erfle, Douglas
; APPLICANT: Fraser, Janet R.
; APPLICANT: West, Michael H.P.
; APPLICANT: McNicol, Patricia J.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION
; TITLE OF INVENTION: WITH ANTIBIOTICS
; FILE REFERENCE: 660081.406
; CURRENT APPLICATION NUMBER: US/09/030,619B
; CURRENT FILING DATE: 1998-02-25
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 204
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Bos taurus
```

US-09-030-619-204

Query Match 100.0%; Score 99; DB 4; Length 13;  
Best Local Similarity 100.0%; Pred. No. 1.1e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
|||||  
Db 1 ILPMKMPMPWRR 13

RESULT 13

US-09-416-481A-1  
; Sequence 1, Application US/09416481A  
; Patent No. 6524585  
; GENERAL INFORMATION:  
; APPLICANT: Selsted, Michael E.  
; TITLE OF INVENTION: Indolizidin Analogs and Methods of Using Same  
; FILE REFERENCE: P-UC 3794  
; CURRENT APPLICATION NUMBER: US/09/416,481A  
; CURRENT FILING DATE: 1999-10-12  
; PRIOR APPLICATION NUMBER: US 09/076,227  
; PRIOR FILING DATE: 1998-05-12  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 1  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; NAME/KEY: MOD\_RES  
; LOCATION: (13)  
; OTHER INFORMATION: AMIDATION  
US-09-416-481A-1

Query Match 100.0%; Score 99; DB 4; Length 13;  
Best Local Similarity 100.0%; Pred. No. 1.1e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
|||||  
Db 1 ILPMKMPMPWRR 13

RESULT 14

US-09-667-486-29  
; Sequence 29, Application US/09667486  
; Patent No. 6538106  
; GENERAL INFORMATION:  
; APPLICANT: Fraser, Janet R.  
; West, Michael H.P.  
; Krieger, Timothy J.  
; Taylor, Robert  
; Erle, Douglas  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING  
; INFECTIONS USING ANALOGUES OF INDOLIZIDIN  
; NUMBER OF SEQUENCES: 90  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: SEED and BERRY LLP  
; STREET: 6300 Columbia Center, 701 Fifth Avenue  
; CITY: Seattle  
; STATE: Washington  
; COUNTRY: USA  
; ZIP: 98104  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/667,486  
FILING DATE: 22-Sep-2000  
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/915,314  
FILING DATE: 20-AUG-1997

ATTORNEY/AGENT INFORMATION:  
NAME: No. 6538106tenburg Ph.D., Carol

REGISTRATION NUMBER: 39,317

REFERENCE/DOCKET NUMBER: 660081.405  
TELEPHONE: (206) 622-4900  
TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 29:

SEQUENCE CHARACTERISTICS:  
LENGTH: 13 amino acids  
TYPE: amino acid  
STRANDEDNESS: <unknown>  
TOPOLOGY: linear

US-09-667-486-29  
; SEQUENCE DESCRIPTION: SEQ ID NO: 29:

Query Match 100.0%; Score 99; DB 4; Length 13;  
Best Local Similarity 100.0%; Pred. No. 1.1e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
|||||  
Db 1 ILPMKMPMPWRR 13

RESULT 15

US-09-076-227-24  
; Sequence 24, Application US/09076227  
; Patent No. 6303575  
; GENERAL INFORMATION:  
; APPLICANT: Selsted, Michael E.  
; TITLE OF INVENTION: Indolizidin Analogs and Methods of Using Same  
; FILE REFERENCE: P-UC 3049  
; CURRENT APPLICATION NUMBER: US/09/076,227  
; CURRENT FILING DATE: 1998-05-12  
; NUMBER OF SEQ ID NOS: 37  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 24  
; LENGTH: 14  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; NAME/KEY: MOD\_RES  
; LOCATION: (14)  
; OTHER INFORMATION: xaa 1s homoserine (Hse).  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: construct  
US-09-076-227-24

Query Match 100.0%; Score 99; DB 4; Length 14;  
Best Local Similarity 100.0%; Pred. No. 1.2e-07;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
|||||  
Db 1 ILPMKMPMPWRR 13

Search completed: October 2, 2003, 10:05:20  
Job time : 26 secs

**HIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 10:04:03 : Search time 65 Seconds  
(without alignments)  
31.643 Million cell updates/sec

Title: US-09-444-281-85  
Perfect score: 99  
Sequence: 1 ILPMKMPWMPWRR 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 587654 seqs, 158212981 residues

Total number of hits satisfying chosen parameters: 587654

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

Published Applications\_AA:\*

- 1: /cgn2\_6/ptodata/2/pubpaa/US07\_PUBCOMB.pep:\*
- 2: /cgn2\_6/ptodata/2/pubpaa/PC7\_NEW\_PUB.pep:\*
- 3: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pep:\*
- 4: /cgn2\_6/ptodata/2/pubpaa/US06\_PUBCOMB.pep:\*
- 5: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pep:\*
- 6: /cgn2\_6/ptodata/2/pubpaa/PC7US\_PUBCOMB.pep:\*
- 7: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pep:\*
- 8: /cgn2\_6/ptodata/2/pubpaa/US08\_PUBCOMB.pep:\*
- 9: /cgn2\_6/ptodata/2/pubpaa/US09\_PUBCOMB.pep:\*
- 10: /cgn2\_6/ptodata/2/pubpaa/US09B\_PUBCOMB.pep:\*
- 11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pep:\*
- 12: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pep:\*
- 13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pep:\*
- 14: /cgn2\_6/ptodata/2/pubpaa/US10B\_PUBCOMB.pep:\*
- 15: /cgn2\_6/ptodata/2/pubpaa/US10C\_PUBCOMB.pep:\*
- 16: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB.pep:\*
- 17: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep:\*
- 18: /cgn2\_6/ptodata/2/pubpaa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	99	100.0	13	9 US-09-030-619-98	Sequence 98, Appl
2	99	100.0	13	9 US-09-030-619-204	Sequence 204, App
3	99	100.0	13	9 US-09-917-340-13	Sequence 13, Appl
4	99	100.0	13	11 US-09-988-792-5	Sequence 5, Appl
5	99	100.0	13	11 US-09-820-053A-42	Sequence 42, Appl
6	99	100.0	13	11 US-09-820-053A-57	Sequence 57, Appl
7	99	100.0	13	12 US-10-229-368-3	Sequence 3, Appl
8	99	100.0	13	12 US-10-229-368-4	Sequence 4, Appl
9	99	100.0	13	12 US-10-225-087-3	Sequence 3, Appl
10	99	100.0	13	12 US-10-225-087-4	Sequence 4, Appl
11	99	100.0	13	15 US-10-109-171-42	Sequence 42, Appl
12	99	100.0	13	15 US-10-109-171-57	Sequence 57, Appl
13	99	100.0	13	16 US-10-252-773-2	Sequence 2, Appl
14	99	100.0	13	9 US-09-909-652-5	Sequence 5, Appl
15	81	81.8	9	9 US-09-030-619-40	Sequence 40, Appl

16	81	81.8	12	12	US-10-229-368-17	Sequence 17, Appl
17	81	81.8	12	12	US-10-225-087-17	Sequence 17, Appl
18	75.5	76.3	15	9	US-09-030-619-39	Sequence 39, Appl
19	75.5	76.3	15	12	US-10-229-368-16	Sequence 16, Appl
20	75.5	76.3	15	12	US-10-225-087-16	Sequence 16, Appl
21	75	75.8	28	9	US-09-030-619-50	Sequence 50, Appl
22	75	75.8	28	12	US-10-229-368-33	Sequence 33, Appl
23	75	75.8	28	12	US-10-229-368-32	Sequence 32, Appl
24	75	75.8	28	12	US-10-225-087-12	Sequence 12, Appl
25	73.5	74.2	13	9	US-09-030-619-107	Sequence 107, Appl
26	73.5	74.2	13	12	US-10-229-368-40	Sequence 40, Appl
27	73.5	74.2	13	12	US-10-225-087-37	Sequence 37, Appl
28	73	73.7	12	9	US-09-030-619-43	Sequence 43, Appl
29	73	73.7	12	9	US-09-030-619-67	Sequence 67, Appl
30	73	73.7	12	9	US-09-030-619-73	Sequence 73, Appl
31	73	73.7	12	9	US-09-030-619-112	Sequence 112, Appl
32	73	73.7	12	12	US-10-229-368-20	Sequence 20, Appl
33	73	73.7	12	12	US-10-229-368-41	Sequence 41, Appl
34	73	73.7	12	12	US-10-229-368-82	Sequence 82, Appl
35	73	73.7	12	12	US-10-229-368-87	Sequence 87, Appl
36	73	73.7	12	12	US-10-225-087-20	Sequence 20, Appl
37	73	73.7	12	12	US-10-225-087-38	Sequence 38, Appl
38	73	73.7	12	12	US-10-225-087-72	Sequence 72, Appl
39	73	73.7	12	12	US-10-225-087-77	Sequence 77, Appl
40	73	73.7	13	9	US-09-030-619-53	Sequence 53, Appl
41	73	73.7	13	9	US-09-030-619-95	Sequence 95, Appl
42	73	73.7	13	9	US-09-030-619-99	Sequence 99, Appl
43	73	73.7	13	9	US-09-030-619-109	Sequence 109, Appl
44	73	73.7	13	12	US-10-229-368-5	Sequence 5, Appl
45	73	73.7	13	12	US-10-229-368-6	Sequence 6, Appl

## ALIGNMENTS

RESULT 1  
US-09-030-619-98  
Sequence 98, Application US/09030619B  
Patent No. US20020035061A1  
GENERAL INFORMATION:  
APPLICANT: Krueger, Timothy J.  
APPLICANT: Taylor, Robert  
APPLICANT: Erfile, Douglas  
APPLICANT: Eraser, Janet R.  
APPLICANT: West, Michael H.P.  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING  
TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION  
FILE REFERENCE: 660081.406  
CURRENT FILING DATE: 1998-02-25  
CURRENT APPLICATION NUMBER: US/09/030,619B  
NUMBER OF SEQ ID NOS: 232  
SOFTWARE: FASTSEQ for Windows Version 3.0  
SEQ ID NO 98  
LENGTH: 13  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Cationic Peptide Analogue  
US-09-030-619-98

Query Match 100.0%: Score 99: DB 9: Length 13:  
Best Local Similarity 100.0%: Pred No. 3.6e-05:  
Matches 13: Conservative 0: Mismatches 0: Indels 0: Gaps 0:

QY 1 ILPMKMPWMPWRR 13  
|||||  
Db 1 ILPMKMPWMPWRR 13

RESULT 2  
US-09-030-619-204

; Sequence 204, Application US/09030619B  
; Patent NO. US20020035061A1  
; GENERAL INFORMATION:  
; APPLICANT: Krieger, Timothy J.  
; APPLICANT: Taylor, Robert  
; APPLICANT: Erfile, Douglas  
; APPLICANT: Eraser, Janet R.  
; APPLICANT: West, Michael H.P.  
; APPLICANT: McNicol, Patricia J.  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING  
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION  
; TITLE OF INVENTION: WITH ANTI-BIOTICS  
; FILE REFERENCE: 660081.406  
; CURRENT APPLICATION NUMBER: US/09/030,619B  
; CURRENT FILING DATE: 1998-02-25  
; NUMBER OF SEQ ID NOS: 232  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 204  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Bos taurus  
US-09-030-619-204

Query Match 100.0%; Score 99; DB 9; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ILPMKMPMPWRR 13  
Db 1 ILPMKMPMPWRR 13

RESULT 3  
US-09-917-340-13  
; Sequence 13, Application US/09917340  
; Patent NO. US20020090369A1  
; GENERAL INFORMATION:  
; APPLICANT: Murphy, Christopher J.  
; APPLICANT: McNulty, Jonathan F.  
; APPLICANT: Reid, Ted W.  
; TITLE OF INVENTION: Transplant Media  
; FILE REFERENCE: TPLANT-06468  
; CURRENT APPLICATION NUMBER: US/09/917,340  
; CURRENT FILING DATE: 2001-07-29  
; PRIOR APPLICATION NUMBER: 60/221,632  
; PRIOR FILING DATE: 2000-07-28  
; PRIOR APPLICATION NUMBER: 60/249,602  
; PRIOR FILING DATE: 2000-11-17  
; PRIOR APPLICATION NUMBER: 60/290,932  
; PRIOR FILING DATE: 2001-05-15  
; NUMBER OF SEQ ID NOS: 96  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 13  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Bos taurus  
US-09-917-340-13

Query Match 100.0%; Score 99; DB 9; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ILPMKMPMPWRR 13  
Db 1 ILPMKMPMPWRR 13

RESULT 4  
US-09-988-792-5  
; Sequence 5, Application US/09988792  
; Publication NO. US20030032599A1  
; GENERAL INFORMATION:  
; APPLICANT: Lipkowski, Andrezej W

; APPLICANT: Carr, Daniel B  
; TITLE OF INVENTION: NOVEL ANTIMICROBIAL COMPOUNDS  
; FILE REFERENCE: 18475-025  
; CURRENT APPLICATION NUMBER: US/09/988,792  
; CURRENT FILING DATE: 2001-11-20  
; PRIOR APPLICATION NUMBER: 60/252,369  
; PRIOR FILING DATE: 2000-11-21  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-988-792-5

Query Match 100.0%; Score 99; DB 11; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ILPMKMPMPWRR 13  
Db 1 ILPMKMPMPWRR 13

RESULT 5  
US-09-820-053A-42  
; Sequence 42, Application US/09820053A  
; Publication NO. US20030083243A1  
; GENERAL INFORMATION:  
; APPLICANT: Owen, Donald R.  
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES  
; FILE REFERENCE: HELX027  
; CURRENT APPLICATION NUMBER: US/09/820,053A  
; CURRENT FILING DATE: 2001-03-28  
; NUMBER OF SEQ ID NOS: 165  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 42  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: ARTIFICIAL SEQUENCE  
; FEATURE:  
; OTHER INFORMATION: SYNTHETIC SEQUENCE  
; NAME/KEY: MOD.RES  
; LOCATION: (13)  
; OTHER INFORMATION: AMIDATION  
US-09-820-053A-42

Query Match 100.0%; Score 99; DB 11; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 ILPMKMPMPWRR 13  
Db 1 ILPMKMPMPWRR 13

RESULT 6  
US-09-820-053A-57  
; Sequence 57, Application US/09820053A  
; Publication NO. US20030083243A1  
; GENERAL INFORMATION:  
; APPLICANT: Owen, Donald R.  
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES  
; FILE REFERENCE: HELX027  
; CURRENT APPLICATION NUMBER: US/09/820,053A  
; CURRENT FILING DATE: 2001-03-28  
; NUMBER OF SEQ ID NOS: 165  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 57  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: ARTIFICIAL SEQUENCE  
; FEATURE:

OTHER INFORMATION: SYNTHETIC SEQUENCE  
US-09-820-053A-57

Query Match 100.0%; Score 99; DB 11; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
DB 1 ILPMKMPMPWRR 13

RESULT 7  
US-10-229-368-3

; Sequence 3, Application US/10229368  
; Publication No. US20030148945A1  
; GENERAL INFORMATION:  
; APPLICANT: MCNICOL, Patricia J.  
; APPLICANT: Pawlak, Sonia K.  
; APPLICANT: Rubinchik, Evelina  
; APPLICANT: Cameron, Dale  
; APPLICANT: Guarina, Maria Martha  
; TITLE OF INVENTION: ANTIMICROBIAL AND ANTI-INFLAMMATORY  
; FILE REFERENCE: 660081.418  
; CURRENT APPLICATION NUMBER: US/10/229,368  
; CURRENT FILING DATE: 2002-08-26  
; NUMBER OF SEQ ID NOS: 140  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Indollicidin peptide analogs  
US-10-229-368-3

Query Match 100.0%; Score 99; DB 12; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
DB 1 ILPMKMPMPWRR 13

RESULT 8

US-10-229-368-4  
; Sequence 4, Application US/10229368  
; Publication No. US20030148945A1  
; GENERAL INFORMATION:  
; APPLICANT: MCNICOL, Patricia J.  
; APPLICANT: Pawlak, Sonia K.  
; APPLICANT: Rubinchik, Evelina  
; APPLICANT: Cameron, Dale  
; APPLICANT: Guarina, Maria Martha  
; TITLE OF INVENTION: ANTIMICROBIAL AND ANTI-INFLAMMATORY  
; FILE REFERENCE: 660081.418  
; CURRENT APPLICATION NUMBER: US/10/229,368  
; CURRENT FILING DATE: 2002-08-26  
; NUMBER OF SEQ ID NOS: 140  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Indollicidin peptide analogs  
US-10-229-368-4

Query Match 100.0%; Score 99; DB 12; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
DB 1 ILPMKMPMPWRR 13

RESULT 9

US-10-225-087-3  
; Sequence 3, Application US/10225087  
; Publication No. US20030171281A1  
; GENERAL INFORMATION:  
; APPLICANT: Krieger, Timothy J.  
; APPLICANT: MCNICOL, Patricia J.  
; APPLICANT: Fraser, Janet R.  
; TITLE OF INVENTION: ANTIMICROBIAL CATIONIC PEPTIDES AND  
; FILE REFERENCE: 660081.417  
; CURRENT APPLICATION NUMBER: US/10/225,087  
; CURRENT FILING DATE: 2003-01-10  
; NUMBER OF SEQ ID NOS: 121  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Indollicidin analog  
US-10-225-087-3

Query Match 100.0%; Score 99; DB 12; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
DB 1 ILPMKMPMPWRR 13

RESULT 10  
US-10-225-087-4  
; Sequence 4, Application US/10225087  
; Publication No. US20030171281A1  
; GENERAL INFORMATION:  
; APPLICANT: Krieger, Timothy J.  
; APPLICANT: MCNICOL, Patricia J.  
; APPLICANT: Fraser, Janet R.  
; TITLE OF INVENTION: ANTIMICROBIAL CATIONIC PEPTIDES AND  
; FILE REFERENCE: 660081.417  
; CURRENT APPLICATION NUMBER: US/10/225,087  
; CURRENT FILING DATE: 2003-01-10  
; NUMBER OF SEQ ID NOS: 121  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Indollicidin analog  
US-10-225-087-4

Query Match 100.0%; Score 99; DB 12; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPWRR 13  
DB 1 ILPMKMPMPWRR 13

RESULT 11  
US-10-109-171-42

; Sequence 42, Application US/10109171  
; Publication No. US20030109452A1  
; GENERAL INFORMATION:  
; APPLICANT: Owen, Donald R.  
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
; FILE REFERENCE: HELX028  
; CURRENT APPLICATION NUMBER: US/10/109,171  
; CURRENT FILING DATE: 2002-03-28  
; NUMBER OF SEQ ID NOS: 165  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 42  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: ARTIFICIAL SEQUENCE  
; FEATURE:  
; OTHER INFORMATION: SYNTHETIC SEQUENCE  
; NAME/KEY: MOD\_RES  
; LOCATION: (13)  
; OTHER INFORMATION: AMIDATION  
US-10-109-171-42

Query Match 100.0%; Score 99; DB 15; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPMPMR 13  
DB 1 ILPMKMPMPMPMR 13

RESULT 12  
US-10-109-171-57  
; Sequence 57, Application US/10109171  
; Publication No. US20030109452A1  
; GENERAL INFORMATION:  
; APPLICANT: Owen, Donald R.  
; TITLE OF INVENTION: SHORT BIOACTIVE PEPTIDES AND METHODS FOR THEIR USE  
; FILE REFERENCE: HELX028  
; CURRENT APPLICATION NUMBER: US/10/109,171  
; CURRENT FILING DATE: 2002-03-28  
; NUMBER OF SEQ ID NOS: 165  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 57  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: ARTIFICIAL SEQUENCE  
; FEATURE:  
; OTHER INFORMATION: SYNTHETIC SEQUENCE  
US-10-109-171-57

Query Match 100.0%; Score 99; DB 15; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPMPMR 13  
DB 1 ILPMKMPMPMPMR 13

RESULT 13  
US-10-252-773-2  
; Sequence 2, Application US/10252773  
; Publication No. US2003013183A1  
; GENERAL INFORMATION:  
; APPLICANT: EVERETT, NICHOLAS P.  
; APPLICANT: LI, QUNINGSHUN  
; APPLICANT: LAWRENCE, CHRISTOPHER  
; APPLICANT: DAVIES, MAELOR H.  
; TITLE OF INVENTION: PEPTIDES WITH ENHANCED STABILITY TO PROTEASE  
; FILE REFERENCE: INTERLINK 3.0-003  
; CURRENT APPLICATION NUMBER: US/10/252,773  
; CURRENT FILING DATE: 2002-09-23

; PRIOR APPLICATION NUMBER: 60/106,373  
; PRIOR FILING DATE: 1998-10-30  
; PRIOR APPLICATION NUMBER: 60/106,573  
; PRIOR FILING DATE: 1998-11-02  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 13  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: antimicrobial peptide  
US-10-252-773-2

Query Match 100.0%; Score 99; DB 16; Length 13;  
Best Local Similarity 100.0%; Pred. No. 3.6e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPMPMR 13  
DB 1 ILPMKMPMPMPMR 13

RESULT 14  
US-09-909-652-5  
; Sequence 5, Application US/09909652  
; Patent No. US20020025537A1  
; GENERAL INFORMATION:  
; APPLICANT: Kairos Scientific, Inc.  
; APPLICANT: Bylina, Edward J.  
; APPLICANT: Coleman, William J.  
; APPLICANT: Youvan, Douglas C.  
; TITLE OF INVENTION: HIGH-THROUGHPUT METHODS FOR GENERATING  
; TITLE OF INVENTION: AND SCREENING COMPOUNDS THAT AFFECT CELL VIABILITY  
; FILE REFERENCE: 22346-7001  
; CURRENT APPLICATION NUMBER: US/09/909,652  
; CURRENT FILING DATE: 2001-10-15  
; PRIOR APPLICATION NUMBER: US 60/219,179  
; PRIOR FILING DATE: 2000-07-19  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 5  
; LENGTH: 19  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Ubiquitin Indolicidin fusion protein fragment  
US-09-909-652-5

Query Match 100.0%; Score 99; DB 9; Length 19;  
Best Local Similarity 100.0%; Pred. No. 4.8e-05;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ILPMKMPMPMPMR 13  
DB 7 ILPMKMPMPMPMR 19

RESULT 15  
US-09-030-619-40  
; Sequence 40, Application US/09030619B  
; Patent No. US20020035061A1  
; GENERAL INFORMATION:  
; APPLICANT: Krieger, Timothy J.  
; APPLICANT: Taylor, Robert  
; APPLICANT: Erfile, Douglas  
; APPLICANT: Fraser, Janet R.  
; APPLICANT: West, Michael H.P.  
; APPLICANT: McNicol, Patricia J.  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING  
; TITLE OF INVENTION: INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION  
; TITLE OF INVENTION: WITH ANTIBIOTICS

FILE REFERENCE: 660081.406  
CURRENT APPLICATION NUMBER: US/09/030,619B  
CURRENT FILING DATE: 1998-02-25  
NUMBER OF SEQ ID NOS: 232  
SOFTWARE: FASTSEQ for Windows Version 3.0  
SEQ ID NO 40  
LENGTH: 12  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Indolicidin Analogue  
US-09-030-619-40

Query Match 81.8%; Score 81; DB 9; Length 12;  
Best Local Similarity 90.0%; Pred No. 0.0033;  
Matches 9; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 4 WKMPMPMPWR 13  
|:|||||||  
DB 2 WRMPMPMPWR 11

Search completed: October 2, 2003, 10:12:53  
Job time : 66 secs

**THIS PAGE BLANK (USPTO)**